aspirin has been researched along with Cholera Infantum in 305 studies
Aspirin: The prototypical analgesic used in the treatment of mild to moderate pain. It has anti-inflammatory and antipyretic properties and acts as an inhibitor of cyclooxygenase which results in the inhibition of the biosynthesis of prostaglandins. Aspirin also inhibits platelet aggregation and is used in the prevention of arterial and venous thrombosis. (From Martindale, The Extra Pharmacopoeia, 30th ed, p5)
acetylsalicylate : A benzoate that is the conjugate base of acetylsalicylic acid, arising from deprotonation of the carboxy group.
acetylsalicylic acid : A member of the class of benzoic acids that is salicylic acid in which the hydrogen that is attached to the phenolic hydroxy group has been replaced by an acetoxy group. A non-steroidal anti-inflammatory drug with cyclooxygenase inhibitor activity.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We randomly assigned patients who had adenomas removed before study entry to receive placebo (679 patients) or 200 mg (685 patients) or 400 mg (671 patients) of celecoxib twice daily." | 9.12 | Celecoxib for the prevention of sporadic colorectal adenomas. ( Anderson, WF; Bagheri, D; Bertagnolli, MM; Boisserie, F; Burn, J; Chung, DC; Corle, D; Dewar, T; Eagle, CJ; Foley, TR; Gordon, GB; Hawk, ET; Hess, TM; Hoffman, N; Kim, K; Macrae, F; Pruitt, RE; Redston, M; Rosenstein, RB; Saltzman, JR; Salzberg, B; Solomon, SD; Sylwestrowicz, T; Tang, J; Viner, JL; Wittes, J; Woloj, GM; Zauber, AG, 2006) |
| "The Prevention of Colorectal Sporadic Adenomatous Polyps trial was a randomized, placebo-controlled, double-blind study of the COX-2 inhibitor celecoxib given daily in a single 400-mg dose." | 9.12 | Celecoxib for the prevention of colorectal adenomatous polyps. ( Arber, N; Bhadra, P; Dite, P; Eagle, CJ; Fowler, R; Gerletti, P; Hajer, J; Lechuga, MJ; Levin, B; Macdonald, K; Rácz, I; Rosenstein, RB; Solomon, SD; Spicak, J; Tang, J; Wittes, J; Zauber, AG; Zavoral, M, 2006) |
| "To evaluate the relative gastrointestinal (GI) tolerability of celecoxib and rofecoxib in elderly hypertensive patients with osteoarthritis (OA) with or without coadministration of low dose aspirin (ASA) (< or = 325 mg daily)." | 9.11 | Cyclooxygenase-2 specific inhibitors and upper gastrointestinal tolerability in patients with osteoarthritis receiving concomitant low dose aspirin: pooled analysis of 2 trials. ( Bello, AE; Fort, JG; Goldstein, JL; Spalding, W; Suh, S, 2005) |
| "To assess the tolerability of rofecoxib compared with naproxen for treatment of osteoarthritis." | 9.10 | Gastrointestinal tolerability and effectiveness of rofecoxib versus naproxen in the treatment of osteoarthritis: a randomized, controlled trial. ( Dixon, ME; Geba, GP; Johansson, G; Lisse, JR; Mollen, AJ; Perlman, M; Polis, AB; Schechtman, J; Shoemaker, JR; Skalky, CS, 2003) |
| "This double-blind, placebo controlled study compared the analgesic efficacy of piroxicam with acetylsalicylic acid (ASA) in patients having continuous pain with advanced head and neck cancers." | 9.07 | Comparison of piroxicam and acetylsalicylic acid for pain in head and neck cancers: a double-blind study. ( Andley, M; Gnanasekaran, N; Saxena, A, 1994) |
| "6 g/day, in 194 patients with rheumatoid arthritis (RA) in Study 1 and with those of naproxen, 1000 mg/day, in 223 patients with RA in Study 2." | 9.06 | Two double blind trials of diclofenac sodium with aspirin and with naproxen in the treatment of patients with rheumatoid arthritis. ( Kolodny, AL, 1988) |
| "Despite a wide range of study designs, a multiplicity of international trials of diclofenac in osteoarthritis have disclosed similar results." | 9.06 | International experiences with diclofenac in osteoarthritis. ( Altman, R, 1986) |
| "The Aspirin Myocardial Infarction Study (AMIS) was a multicenter, randomized, double-blind, placebo-controlled trial of 1." | 9.05 | The aspirin myocardial infarction study: final results. The Aspirin Myocardial Infarction Study research group. ( , 1980) |
| "In a double-blind, multiclinic study, 437 patients with osteoarthritis were treated sequentially with ibuprofen, 1,800 mg/day, and placebo, or with aspirin, 3,600 mg/day, and placebo." | 9.04 | Ibuprofen in osteoarthritis. ( Brooks, CD; Donaldson, MS; Giansiracusa, JE; Koonce, ML; Lefton, TE; Ruoff, GE, 1977) |
| "Pirprofen (800 mg/day) or aspirin (3,600 mg/day) was administered in double-blind fashion for up to one year to 40 adult outpatients with rheumatoid arthritis, after a short, single-blind placebo period." | 9.04 | Pirprofen and aspirin in the treatment of rheumatoid arthritis. ( Davis, JD; Pisko, EJ; Ruchte, IR; Struth, AG; Turner, RA, 1979) |
| "The objective of the study was to compare efficacy and safety of Fenbufen and Aspirin in osteoarthritis." | 9.04 | Clinical comparison of fenbufen and aspirin in osteoarthritis. ( Valtonen, EJ, 1979) |
| "Aspirin is indicated for primary and secondary prevention of cardiovascular diseases (CVD) by major guidelines." | 8.95 | Efficacy of aspirin (325 mg) + omeprazole (40 mg) in treating coronary artery disease. ( Bliden, K; Chaudhary, R; Gurbel, PA; Sharma, T; Tantry, U, 2017) |
| "Acetylsalicylic acid (ASA [aspirin]) is a commonly used over-the-counter drug for the treatment of pain, fever, or colds, but data on the safety of this use are very limited." | 8.87 | Short-term acetylsalicylic acid (aspirin) use for pain, fever, or colds - gastrointestinal adverse effects: a meta-analysis of randomized clinical trials. ( Baron, JA; Brueckner, A; Lanas, A; McCarthy, D; Senn, S; Voelker, M, 2011) |
| "The frequencies of all and GI adverse events (AEs) and adverse drug reactions (ADRs) were calculated from the pooled individual patient data of nine similar randomized, double-blind, placebo controlled clinical trials of single-doses of aspirin 1000 mg in the treatment of acute migraine attacks, episodic tension-type headache and dental pain." | 8.85 | Gastrointestinal tolerability of aspirin and the choice of over-the-counter analgesia for short-lasting acute pain. ( Steiner, TJ; Voelker, M, 2009) |
| "A prespecified pooled intent-to-treat analysis of three double-blind randomised comparisons of etoricoxib (60 or 90 mg daily) and diclofenac (150 mg daily) in 34 701 patients with osteoarthritis or rheumatoid arthritis was done for upper gastrointestinal clinical events (bleeding, perforation, obstruction, or ulcer) and the subset of complicated events (perforation, obstruction, witnessed ulcer bleeding, or significant bleeding)." | 8.84 | Assessment of upper gastrointestinal safety of etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison. ( Cannon, CP; Cryer, B; Curtis, SP; Kaur, A; Laine, L, 2007) |
| "Aspirin for prevention of colorectal cancer is controversial." | 8.84 | The use of aspirin for primary prevention of colorectal cancer: a systematic review prepared for the U.S. Preventive Services Task Force. ( Barrowman, N; Code, C; Dubé, C; Lewin, G; Moher, D; Rostom, A; Sampson, M; Tsertsvadze, A, 2007) |
| "To determine the efficacy, gastrointestinal safety, and tolerability of celecoxib (a cyclo-oxygenase 2 (COX 2) inhibitor) used in the treatment of osteoarthritis and rheumatoid arthritis." | 8.81 | Efficacy, tolerability, and upper gastrointestinal safety of celecoxib for treatment of osteoarthritis and rheumatoid arthritis: systematic review of randomised controlled trials. ( Bradley, MD; Deeks, JJ; Smith, LA, 2002) |
| " Preventive Services Task Force (USPSTF) recommendation and supporting scientific evidence on routine use of aspirin or nonsteroidal anti-inflammatory drugs for the primary prevention of colorectal cancer." | 7.74 | Routine aspirin or nonsteroidal anti-inflammatory drugs for the primary prevention of colorectal cancer: U.S. Preventive Services Task Force recommendation statement. ( , 2007) |
| "The effect of combination NSAID therapy of tilomisole with aspirin or naproxen was studied in rats with carrageenan-induced paw edema and established adjuvant arthritis." | 7.68 | Interaction studies of tilomisole, aspirin, and naproxen in acute and chronic inflammation with assessment of gastrointestinal irritancy in the rat. ( Calhoun, W; Carlson, RP; Copenhaver, TW; Datko, LJ; Gilman, SC, 1992) |
| "Conventional nonsteroidal anti-inflammatory drugs (NSAIDs) are associated with a spectrum of toxic effects, notably gastrointestinal (GI) effects, because of inhibition of cyclooxygenase (COX)-1." | 6.69 | Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. ( Agrawal, NM; Burr, AM; Eisen, G; Faich, G; Geis, GS; Goldstein, JL; Kent, JD; Lefkowith, JB; Makuch, R; Pincus, T; Silverstein, FE; Simon, LS; Stenson, WF; Verburg, KM; Whelton, A; Zhao, WW, 2000) |
| "Ketoprofen was preferred more often by the patients while the investigator found it acceptable as often as aspirin." | 6.64 | A double-blind cross-over evaluation of ketoprofen and aspirin in rheumatoid arthritis. ( Camerlain, M; Lussier, A; Menard, H; Myhal, D; Wehner, S, 1976) |
| " Almost half of the patients taking aspirin were unable to tolerate the drug in adequate dosage for six months." | 6.64 | Treatment of rheumatoid arthritis with fenoprofen: comparison with aspirin. ( Balme, HW; Berry, H; Hart, FD; Huskisson, EC; Scott, J; Wojtulewski, JA, 1974) |
| "Thirty-six randomized control trials of aspirin compared with another dosage of aspirin or with placebo." | 6.39 | Efficacy and safety of different aspirin dosages on vascular diseases in high-risk patients. A metaregression analysis. ( Cappelleri, JC; Chalmers, TC; Kupelnick, B; Lau, J, 1995) |
| " Given the low rates of events, at low or intermittent dosage without concurrent treatment, these 3 analgesics cannot be distinguished from each other or from background rates of serious GI toxicity." | 5.32 | Rates of serious gastrointestinal events from low dose use of acetylsalicylic acid, acetaminophen, and ibuprofen in patients with osteoarthritis and rheumatoid arthritis. ( Bruce, B; Fries, JF, 2003) |
| " Osteoarthritis or rheumatoid arthritis patients, needing ongoing NSAID treatment, were randomised to receive celecoxib 100-200 mg b." | 5.27 | Randomised clinical trial: gastrointestinal events in arthritis patients treated with celecoxib, ibuprofen or naproxen in the PRECISION trial. ( Bao, W; Borer, JS; Graham, DY; Husni, ME; Libby, P; Lincoff, AM; Lüscher, TF; Nissen, SE; Solomon, DH; Stevens, T; Vargo, J; Walker, C; Wang, Q; Wisniewski, LM; Wolski, KE; Yeomans, ND, 2018) |
| "We randomly assigned patients who had adenomas removed before study entry to receive placebo (679 patients) or 200 mg (685 patients) or 400 mg (671 patients) of celecoxib twice daily." | 5.12 | Celecoxib for the prevention of sporadic colorectal adenomas. ( Anderson, WF; Bagheri, D; Bertagnolli, MM; Boisserie, F; Burn, J; Chung, DC; Corle, D; Dewar, T; Eagle, CJ; Foley, TR; Gordon, GB; Hawk, ET; Hess, TM; Hoffman, N; Kim, K; Macrae, F; Pruitt, RE; Redston, M; Rosenstein, RB; Saltzman, JR; Salzberg, B; Solomon, SD; Sylwestrowicz, T; Tang, J; Viner, JL; Wittes, J; Woloj, GM; Zauber, AG, 2006) |
| "The Prevention of Colorectal Sporadic Adenomatous Polyps trial was a randomized, placebo-controlled, double-blind study of the COX-2 inhibitor celecoxib given daily in a single 400-mg dose." | 5.12 | Celecoxib for the prevention of colorectal adenomatous polyps. ( Arber, N; Bhadra, P; Dite, P; Eagle, CJ; Fowler, R; Gerletti, P; Hajer, J; Lechuga, MJ; Levin, B; Macdonald, K; Rácz, I; Rosenstein, RB; Solomon, SD; Spicak, J; Tang, J; Wittes, J; Zauber, AG; Zavoral, M, 2006) |
| "To evaluate the relative gastrointestinal (GI) tolerability of celecoxib and rofecoxib in elderly hypertensive patients with osteoarthritis (OA) with or without coadministration of low dose aspirin (ASA) (< or = 325 mg daily)." | 5.11 | Cyclooxygenase-2 specific inhibitors and upper gastrointestinal tolerability in patients with osteoarthritis receiving concomitant low dose aspirin: pooled analysis of 2 trials. ( Bello, AE; Fort, JG; Goldstein, JL; Spalding, W; Suh, S, 2005) |
| "To assess the tolerability of rofecoxib compared with naproxen for treatment of osteoarthritis." | 5.10 | Gastrointestinal tolerability and effectiveness of rofecoxib versus naproxen in the treatment of osteoarthritis: a randomized, controlled trial. ( Dixon, ME; Geba, GP; Johansson, G; Lisse, JR; Mollen, AJ; Perlman, M; Polis, AB; Schechtman, J; Shoemaker, JR; Skalky, CS, 2003) |
| "Compared with aspirin, clopidogrel reduced the combined risk of ischaemic stroke, myocardial infarction or vascular death by 8." | 5.09 | Comparative safety and tolerability of clopidogrel and aspirin: results from CAPRIE. CAPRIE Steering Committee and Investigators. Clopidogrel versus aspirin in patients at risk of ischaemic events. ( Boissel, JP; Gent, M; Harker, LA; Pilgrim, AJ, 1999) |
| "To determine the effectiveness of aspirin in preventing ischemic events in patients with asymptomatic carotid stenosis." | 5.08 | Lack of effect of aspirin in asymptomatic patients with carotid bruits and substantial carotid narrowing. The Asymptomatic Cervical Bruit Study Group. ( Abrahamowicz, M; Battista, RN; Bourque, F; Côté, R; Langlois, Y; Mackey, A, 1995) |
| "This double-blind, placebo controlled study compared the analgesic efficacy of piroxicam with acetylsalicylic acid (ASA) in patients having continuous pain with advanced head and neck cancers." | 5.07 | Comparison of piroxicam and acetylsalicylic acid for pain in head and neck cancers: a double-blind study. ( Andley, M; Gnanasekaran, N; Saxena, A, 1994) |
| "6 g/day, in 194 patients with rheumatoid arthritis (RA) in Study 1 and with those of naproxen, 1000 mg/day, in 223 patients with RA in Study 2." | 5.06 | Two double blind trials of diclofenac sodium with aspirin and with naproxen in the treatment of patients with rheumatoid arthritis. ( Kolodny, AL, 1988) |
| "Despite a wide range of study designs, a multiplicity of international trials of diclofenac in osteoarthritis have disclosed similar results." | 5.06 | International experiences with diclofenac in osteoarthritis. ( Altman, R, 1986) |
| " Gastrointestinal side effects with benoxaprofen compared favorably to those reported during aspirin and ibuprofen therapy, with peptic ulcers reported in 0." | 5.05 | Long-term safety of benoxaprofen. ( Mikulaschek, WM, 1980) |
| "The Aspirin Myocardial Infarction Study (AMIS) was a multicenter, randomized, double-blind, placebo-controlled trial of 1." | 5.05 | The aspirin myocardial infarction study: final results. The Aspirin Myocardial Infarction Study research group. ( , 1980) |
| "Data collected from more than 1,800 patients with rheumatoid arthritis or degenerative joint disease in Phase 3 clinical studies of isoxicam (Maxicam) indicated that the drug is well tolerated on both a short-term and a long-term basis." | 5.05 | Evaluation of the safety of isoxicam. ( Burch, FX, 1985) |
| "In a double-blind, multiclinic study, 437 patients with osteoarthritis were treated sequentially with ibuprofen, 1,800 mg/day, and placebo, or with aspirin, 3,600 mg/day, and placebo." | 5.04 | Ibuprofen in osteoarthritis. ( Brooks, CD; Donaldson, MS; Giansiracusa, JE; Koonce, ML; Lefton, TE; Ruoff, GE, 1977) |
| "Pirprofen (800 mg/day) or aspirin (3,600 mg/day) was administered in double-blind fashion for up to one year to 40 adult outpatients with rheumatoid arthritis, after a short, single-blind placebo period." | 5.04 | Pirprofen and aspirin in the treatment of rheumatoid arthritis. ( Davis, JD; Pisko, EJ; Ruchte, IR; Struth, AG; Turner, RA, 1979) |
| "The objective of the study was to compare efficacy and safety of Fenbufen and Aspirin in osteoarthritis." | 5.04 | Clinical comparison of fenbufen and aspirin in osteoarthritis. ( Valtonen, EJ, 1979) |
| " Known side effects of aspirin-tinnitus, deafness, and gastrointestinal disturbance-were more efficiently shown and symptoms not included in the check list were more likely to be reported when a check list was not used." | 5.04 | Measurement of side effects of drugs. ( Huskisson, EC; Wojtulewski, JA, 1974) |
| "Aspirin is indicated for primary and secondary prevention of cardiovascular diseases (CVD) by major guidelines." | 4.95 | Efficacy of aspirin (325 mg) + omeprazole (40 mg) in treating coronary artery disease. ( Bliden, K; Chaudhary, R; Gurbel, PA; Sharma, T; Tantry, U, 2017) |
| "This study compared proton pump inhibitors (PPIs) and histamine H2 receptor antagonists (H2RAs) for prevention of low-dose aspirin (LDA)-related gastrointestinal (GI) erosion, ulcer and bleeding." | 4.91 | PPI versus Histamine H2 Receptor Antagonists for Prevention of Upper Gastrointestinal Injury Associated with Low-Dose Aspirin: Systematic Review and Meta-analysis. ( Lu, ML; Mo, C; Sun, G; Wang, YZ; Yang, YS, 2015) |
| " In absolute terms, these relative risks indicate that for every 10,000 diabetic patients treated with aspirin, 109 MACE may be prevented at the expense of 19 major bleeding events (with the caveat that the relative risk for the latter is not statistically significant)." | 4.87 | Aspirin effect on the incidence of major adverse cardiovascular events in patients with diabetes mellitus: a systematic review and meta-analysis. ( Butalia, S; Ghali, WA; Leung, AA; Rabi, DM, 2011) |
| "Acetylsalicylic acid (ASA [aspirin]) is a commonly used over-the-counter drug for the treatment of pain, fever, or colds, but data on the safety of this use are very limited." | 4.87 | Short-term acetylsalicylic acid (aspirin) use for pain, fever, or colds - gastrointestinal adverse effects: a meta-analysis of randomized clinical trials. ( Baron, JA; Brueckner, A; Lanas, A; McCarthy, D; Senn, S; Voelker, M, 2011) |
| "The frequencies of all and GI adverse events (AEs) and adverse drug reactions (ADRs) were calculated from the pooled individual patient data of nine similar randomized, double-blind, placebo controlled clinical trials of single-doses of aspirin 1000 mg in the treatment of acute migraine attacks, episodic tension-type headache and dental pain." | 4.85 | Gastrointestinal tolerability of aspirin and the choice of over-the-counter analgesia for short-lasting acute pain. ( Steiner, TJ; Voelker, M, 2009) |
| "A prespecified pooled intent-to-treat analysis of three double-blind randomised comparisons of etoricoxib (60 or 90 mg daily) and diclofenac (150 mg daily) in 34 701 patients with osteoarthritis or rheumatoid arthritis was done for upper gastrointestinal clinical events (bleeding, perforation, obstruction, or ulcer) and the subset of complicated events (perforation, obstruction, witnessed ulcer bleeding, or significant bleeding)." | 4.84 | Assessment of upper gastrointestinal safety of etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison. ( Cannon, CP; Cryer, B; Curtis, SP; Kaur, A; Laine, L, 2007) |
| "Aspirin for prevention of colorectal cancer is controversial." | 4.84 | The use of aspirin for primary prevention of colorectal cancer: a systematic review prepared for the U.S. Preventive Services Task Force. ( Barrowman, N; Code, C; Dubé, C; Lewin, G; Moher, D; Rostom, A; Sampson, M; Tsertsvadze, A, 2007) |
| "This review examines ulcers and gastrointestinal bleeding with low-dose aspirin, focusing on randomized placebo-controlled trials." | 4.83 | Review article: gastrointestinal bleeding with low-dose aspirin - what's the risk? ( Laine, L, 2006) |
| "Ulcer complications associated with the use of NSAIDs, in high-risk patients, are often caused by a failure to identify patients' risk factors, concomitant use of aspirin or multiple NSAIDs, and underutilization of gastroprotective agents." | 4.83 | Primer: managing NSAID-induced ulcer complications--balancing gastrointestinal and cardiovascular risks. ( Chan, FK, 2006) |
| "To determine the efficacy, gastrointestinal safety, and tolerability of celecoxib (a cyclo-oxygenase 2 (COX 2) inhibitor) used in the treatment of osteoarthritis and rheumatoid arthritis." | 4.81 | Efficacy, tolerability, and upper gastrointestinal safety of celecoxib for treatment of osteoarthritis and rheumatoid arthritis: systematic review of randomised controlled trials. ( Bradley, MD; Deeks, JJ; Smith, LA, 2002) |
| "The clinical benefit of aspirin in coronary insufficiency has been validated in the acute phase of myocardial infarction and in secondary prevention with a reduction of the risk of recurrent infarction of the order of 30%." | 4.79 | [Aspirin in secondary cardiovascular prevention: from clinical studies to daily practice]. ( Garnier, LF, 1997) |
| " Aspirin and all nonsalicylate NSAIDs share a risk of causing gastric ulcer, upper GI bleeding, and GI perforation." | 4.78 | Cost-conscious prescribing of nonsteroidal anti-inflammatory drugs for adults with arthritis. A review and suggestions. ( Greene, JM; Winickoff, RN, 1992) |
| " The nonacetylated salicylates appear to have fewer adverse effects than either aspirin or the NSAIDs and therefore may warrant greater consideration as first-line therapy for arthritis." | 4.77 | Salicylates in the treatment of arthritic disease. How safe and effective? ( Altman, RD, 1988) |
| "Gastroduodenal ulcer and erosion are common in Japanese patients taking low dose aspirin for cardioprotection." | 3.80 | Risk factor profiles, drug usage, and prevalence of aspirin-associated gastroduodenal injuries among high-risk cardiovascular Japanese patients: the results from the MAGIC study. ( Goto, S; Hiraishi, H; Ikeda, Y; Okada, Y; Origasa, H; Shimada, K; Sugano, K; Uchiyama, S; Uemura, N, 2014) |
| "The Japanese health insurance system approved the use of proton pump inhibitors (PPIs) for the prevention of peptic ulcers in patients using low-dose aspirin (LDA) and/or non-steroidal anti-inflammatory drugs (NSAIDs)." | 3.80 | Proton pump inhibitor treatment decreases the incidence of upper gastrointestinal disorders in elderly Japanese patients treated with NSAIDs. ( Fukuda, S; Mikami, T; Nakagawa, S; Sakamoto, Y; Shimoyama, T, 2014) |
| "We have previously shown that co-treatment of angiotensin type 1 receptor (AT1R) blocker (ARB) or angiotensin converting enzyme (ACE) inhibitor seem to reduce peptic ulcer among patients taking low dose aspirin." | 3.77 | Renin-angiotensin system associated with risk of upper GI mucosal injury induced by low dose aspirin: renin angiotensin system genes' polymorphism. ( Haruma, K; Kamada, T; Matsumoto, H; Murao, T; Nishi, R; Sakakibara, T; Shiotani, A; Tarumi, K; Yamanaka, Y, 2011) |
| "Phospho-aspirin, phospho-ibuprofen and phospho-sulindac were safer than their parent NSAIDs, were highly effective in rat adjuvant arthritis and inhibited many key mediators in the pathophysiology of RA." | 3.77 | The novel phospho-non-steroidal anti-inflammatory drugs, OXT-328, MDC-22 and MDC-917, inhibit adjuvant-induced arthritis in rats. ( Huang, L; Johnson, F; Komninou, D; Mackenzie, G; Ouyang, N; Rigas, B; Sun, Y; Xie, G, 2011) |
| " Preventive Services Task Force (USPSTF) recommendation and supporting scientific evidence on routine use of aspirin or nonsteroidal anti-inflammatory drugs for the primary prevention of colorectal cancer." | 3.74 | Routine aspirin or nonsteroidal anti-inflammatory drugs for the primary prevention of colorectal cancer: U.S. Preventive Services Task Force recommendation statement. ( , 2007) |
| "Over 60% of aspirin users are above 60 years of age, 4 to 6% have a recent history of peptic ulcers and over 13% use other non-steroidal anti-inflammatory drugs." | 3.73 | Cardioprotective aspirin users and their excess risk of upper gastrointestinal complications. ( García Rodríguez, LA; Hernández-Díaz, S, 2006) |
| "The effect of combination NSAID therapy of tilomisole with aspirin or naproxen was studied in rats with carrageenan-induced paw edema and established adjuvant arthritis." | 3.68 | Interaction studies of tilomisole, aspirin, and naproxen in acute and chronic inflammation with assessment of gastrointestinal irritancy in the rat. ( Calhoun, W; Carlson, RP; Copenhaver, TW; Datko, LJ; Gilman, SC, 1992) |
| " In carrageenin-induced oedema indoprofen and prednisolone had a synergistic anti-inflammatory effect, and indoprofen and acetylsalicylic acid showed an additive effect." | 3.66 | Preclinical studies on indoprofen, a new non-steroidal analgesic-antiinflammatory agent. ( Buttinoni, A; Tommasini, R, 1981) |
| " The secondary endpoint is a composite of major adverse cardiovascular and cerebrovascular events (MACCE), including all-cause death, cardiac death, nonfatal myocardial infarction, stent thrombosis, ischemia-driven target vessel revascularization, and stroke." | 3.30 | Efficacy and safety of rivaroxaban plus clopidogrel versus aspirin plus clopidogrel in patients with coronary atherosclerotic heart disease and gastrointestinal disease undergoing percutaneous coronary intervention: study protocol for a non-inferiority ra ( Gong, Y; Li, J; Wang, X; Wang, Y; Zhou, T, 2023) |
| " Endpoints were adverse events (AEs) of any kind and, especially of gastrointestinal (GI) nature." | 3.01 | Comparison of gastrointestinal adverse events between fast release tablets and regular acetylsalicylic acid (aspirin) galenics after short-term use: a meta-analysis of randomized clinical trials. ( Lanas, A; Mikhail, E; Werz, O, 2023) |
| " In the pooled analysis from all five studies, incidences of treatment-emergent adverse events (AEs) (including prespecified NSAID-associated upper GI AEs and cardiovascular AEs), serious AEs, and AE-related discontinuations were stratified by LDA subgroups." | 2.79 | Impact of concomitant low-dose aspirin on the safety and tolerability of naproxen and esomeprazole magnesium delayed-release tablets in patients requiring chronic nonsteroidal anti-inflammatory drug therapy: an analysis from 5 Phase III studies. ( Angiolillo, DJ; Datto, C; Raines, S; Yeomans, ND, 2014) |
| "Although low-dose acetylsalicylic acid (ASA) is recommended for prevention of cardiovascular events in at-risk patients, its long-term use can be associated with the risk of peptic ulcer and upper gastrointestinal (GI) symptoms that may impact treatment compliance." | 2.78 | Esomeprazole for prevention and resolution of upper gastrointestinal symptoms in patients treated with low-dose acetylsalicylic acid for cardiovascular protection: the OBERON trial. ( Agewall, S; Herlitz, J; Lanas, A; Nagy, P; Nauclér, EC; Scheiman, JM; Svedberg, LE; Veldhuyzen van Zanten, SJ, 2013) |
| " Two 7-day treatments were separated by 14-day washout periods: (a) PA32540 + clopidogrel (300 mg loading/75 mg maintenance) 10 hours later and (b) synchronous dosing of clopidogrel + EC aspirin (81 mg) + EC omeprazole (40 mg)." | 2.78 | Spaced administration of PA32540 and clopidogrel results in greater platelet inhibition than synchronous administration of enteric-coated aspirin and enteric-coated omeprazole and clopidogrel. ( Antonino, M; Bliden, KP; Chai, S; Fort, JG; Gesheff, M; Gesheff, T; Gurbel, PA; Jeong, YH; Shuldiner, A; Tantry, US; Zhang, Y, 2013) |
| "Conventional nonsteroidal anti-inflammatory drugs (NSAIDs) are associated with a spectrum of toxic effects, notably gastrointestinal (GI) effects, because of inhibition of cyclooxygenase (COX)-1." | 2.69 | Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. ( Agrawal, NM; Burr, AM; Eisen, G; Faich, G; Geis, GS; Goldstein, JL; Kent, JD; Lefkowith, JB; Makuch, R; Pincus, T; Silverstein, FE; Simon, LS; Stenson, WF; Verburg, KM; Whelton, A; Zhao, WW, 2000) |
| " Documentation is derived from clinical trials, post-marketing surveillance, special studies, and spontaneous reports of adverse drug reactions from foreign countries." | 2.66 | Worldwide safety experience with diclofenac. ( Catalano, MA, 1986) |
| "Since its introduction in the United States in 1974, ibuprofen (Motrin, Upjohn) has been shown to be safe and effective for the treatment of pain, dysmenorrhea, inflammation, and fever." | 2.65 | Safety profile: fifteen years of clinical experience with ibuprofen. ( Royer, GL; Seckman, CE; Welshman, IR, 1984) |
| "Flurbiprofen was found to have produced minor changes which tended to be localized." | 2.64 | Endoscopic study of gastro-intestinal injury with non-steroidal anti-inflammatory drugs. ( Dalal, NJ; Pispati, PK; Shah, PN; Vakil, BJ; Wagholikar, UN, 1977) |
| "Ketoprofen was preferred more often by the patients while the investigator found it acceptable as often as aspirin." | 2.64 | A double-blind cross-over evaluation of ketoprofen and aspirin in rheumatoid arthritis. ( Camerlain, M; Lussier, A; Menard, H; Myhal, D; Wehner, S, 1976) |
| " Almost half of the patients taking aspirin were unable to tolerate the drug in adequate dosage for six months." | 2.64 | Treatment of rheumatoid arthritis with fenoprofen: comparison with aspirin. ( Balme, HW; Berry, H; Hart, FD; Huskisson, EC; Scott, J; Wojtulewski, JA, 1974) |
| "Aspirin is a commonly used over-the-counter (OTC) agent for the symptomatic treatment of acute pain, fever, or the common cold, but data regarding safety in this context are limited." | 2.53 | Gastrointestinal Safety of Aspirin for a High-Dose, Multiple-Day Treatment Regimen: A Meta-Analysis of Three Randomized Controlled Trials. ( Forder, S; Lanas, A; Voelker, M, 2016) |
| "Aspirin has been one of the most widely used medications since its first synthesis more than 100 years ago." | 2.52 | Aspirin Use on Incidence and Mortality of Gastrointestinal Cancers: Current State of Epidemiological Evidence. ( Huang, WK; See, LC; Tu, HT, 2015) |
| " Furthermore, it has been demonstrated that chronic use of low dose ASA results in a variety of lesions in the lower GI tract, including multiple petechiae, erosions, ulcers, diverticular bleeding and even circumferential ulcers with stricture." | 2.52 | Epidemiology of Low Dose Aspirin Damage in the Lower Gastrointestinal Tract. ( Lanas, A; Sostres, C, 2015) |
| "Aspirin was associated with a higher risk of minor gastrointestinal events than placebo or active comparators: the summary ORs were 1." | 2.49 | Gastrointestinal adverse effects of short-term aspirin use: a meta-analysis of published randomized controlled trials. ( Baron, JA; Brückner, A; Lanas, A; Laurora, I; McCarthy, D; Senn, S; Thielemann, W; Voelker, M, 2013) |
| "Second, new findings about postoperative pain management in patients with preoperative pain and chronic opioid consumption are reported." | 2.48 | Room for improvement: unmet needs in postoperative pain management. ( Pogatzki-Zahn, EM; Schnabel, A; Zahn, PK, 2012) |
| " Until further reliable controlled data are available, this potential, but currently unproven, clinical interaction can be minimized by widely separating the dosing of clopidogrel and PPI." | 2.46 | NSAID-induced gastrointestinal and cardiovascular injury. ( Chan, FK; Ng, SC, 2010) |
| " Off-label long-term use of COX2 inhibitors in patients with a history of colorectal adenomas in well-designed, placebo-controlled trials showed that treatment with these agents is associated with an increased rate of cardiovascular adverse effects." | 2.44 | Drug insight: cyclo-oxygenase-2 inhibitors--a critical appraisal. ( Brune, K; Hinz, B; Renner, B, 2007) |
| "Helicobacter pylori (H pylori) infection and the use of non-steroidal anti-inflammatory drugs (NSAIDs) including aspirin at any dosage and formulation represent well-established risk factors for the development of uncomplicated and complicated peptic ulcer disease accounting for the majority of such cases." | 2.43 | Role of Helicobacter pylori eradication in aspirin or non-steroidal anti-inflammatory drug users. ( Archimandritis, AJ; Papatheodoridis, GV, 2005) |
| "Aspirin has a role in the prevention of cardiovascular and cerebrovascular disease, Alzheimer's dementia and several cancers." | 2.42 | Review article: the ageing bowel and intolerance to aspirin. ( Johns, CE; May, FE; Newton, JL, 2004) |
| " Unlike selective COX-2 inhibitors, coadministration of licofelone and aspirin does not appear to be associated with an increase in gastrointestinal adverse events, at least under experimental conditions." | 2.42 | Safety of anti-inflammatory treatment--new ways of thinking. ( Brune, K, 2004) |
| "Aspirin is a very useful medication for the prevention of cardiovascular thrombotic events in patients with or those at risk for cardiovascular disease (CVD)." | 2.42 | Cardioprotective effects and gastrointestinal risks of aspirin: maintaining the delicate balance. ( Kimmey, MB, 2004) |
| "Aspirin was associated with UGIC even when used at low doses or in buffered or enteric-coated formulations." | 2.41 | Association between aspirin and upper gastrointestinal complications: systematic review of epidemiologic studies. ( de Abajo, FJ; García Rodríguez, LA; Hernández-Díaz, S, 2001) |
| "Thirty-six randomized control trials of aspirin compared with another dosage of aspirin or with placebo." | 2.39 | Efficacy and safety of different aspirin dosages on vascular diseases in high-risk patients. A metaregression analysis. ( Cappelleri, JC; Chalmers, TC; Kupelnick, B; Lau, J, 1995) |
| "Chronic gastric ulcer is linked to aspirin intake in patients with rheumatic disease, and epidemiologically in all heavy aspirin users; paradoxically, in only one epidemiologic study was a significant association found between acetaminophen intake and chronic gastric ulcer." | 2.36 | Gastrointestinal effects of antipyretic analgesics. ( Ivey, KJ, 1983) |
| "Different dosage forms of ASA are characterized with similar efficacy in prevention of cardiovascular events and effects on the risk of bleeding." | 1.51 | [Predictors for development of major cardiovascular events in elderly patients with severe and extremely severe chronic obstructive pulmonary disease in combination with early stages of chronic kidney disease]. ( Erofeeva, SG; Karpukhina, EV; Nekrasov, AA; Timoshchenko, ES, 2019) |
| "The Aspirin-Cardio treatment reduced the mean score of GI symptom severity from the questionnaire (1." | 1.46 | [Safety and efficacy of long-term treatment with different ASA forms in patients with stable IHD and a high risk for development of gastropathy by data from a cross-sectionals study]. ( Karpukhina, EV; Nekrasov, AA; Petelina, IS; Timoshchenko, ES, 2017) |
| "Evidence for cancer prophylaxis is based on ASA doses of at least 75mg/day." | 1.43 | Aspirin for cancer is no mere antiplatelet prototype. There is potential in its ancient roots. ( Baxter, GJ; Lawrence, JR; Paterson, JR, 2016) |
| " The reference dose of Diclofenac used in all randomized controlled trials is 150 mg/die; this controlled release dosage allows to decrease the number of daily administrations, ensuring a better patient compliance, especially if elderly and/or in polytherapy." | 1.40 | [Diclofenac: update on tolerableness and spinal anti-inflammatory action]. ( Sandri, A, 2014) |
| "88) whereas neither, gender nor aspirin dosage (ranging from 75 and 325 mg) predicted the occurrence of UGS." | 1.38 | Prevalence and clinical impact of Upper Gastrointestinal Symptoms in subjects treated with low dose aspirin: the UGLA survey. ( Cayla, G; Collet, JP; Montalescot, G; Silvain, J; Thiefin, G; Woimant, F, 2012) |
| "We investigated dosage regimens for aspirin therapy in regard to antiplatelet effects in patients without gastrointestinal lesions." | 1.38 | Theoretical investigation of aspirin dosage regimen to exhibit optimal antiplatelet effects and decrease risk of upper gastrointestinal lesions. ( Kitagawa, Y; Suzuki, Y; Tokuoka, K; Watanabe, M; Yaguchi, T; Yamada, Y; Yokoyama, H, 2012) |
| " Subjects were eligible for inclusion in the study if they received an OTC dosage of naproxen (220 mg) or ibuprofen (200 mg)." | 1.33 | Gastrointestinal complications of over-the-counter nonsteroidal antiinflammatory drugs. ( Biskupiak, JE; Brixner, DI; Howard, K; Oderda, GM, 2006) |
| " Given the low rates of events, at low or intermittent dosage without concurrent treatment, these 3 analgesics cannot be distinguished from each other or from background rates of serious GI toxicity." | 1.32 | Rates of serious gastrointestinal events from low dose use of acetylsalicylic acid, acetaminophen, and ibuprofen in patients with osteoarthritis and rheumatoid arthritis. ( Bruce, B; Fries, JF, 2003) |
| "Erosive gastritis was noted more frequently in the aspirin group than in the control group." | 1.32 | [Gastroduodenal injury in patients with low-dose enteric coated aspirin treatment]. ( Ahn, YH; Hahm, JS; Han, DS; Kim, JB; Lee, HL; Park, JY; Sohn, JH, 2003) |
| " Serious adverse events were uncommon but despite this aspirin cost the NHS between 6 and 25 times the cost of aspirin tablets due to dispensing costs and the cost of managing adverse effects." | 1.32 | Cardiovascular prophylaxis with aspirin: costs of supply and management of upper gastrointestinal and renal toxicity. ( Cleland, JG; Davey, PG; MacDonald, TM; McMahon, AD; Morant, SV, 2004) |
| "Etodolac is a generic nonsteroidal anti-inflammatory drug (NSAID)." | 1.32 | Risks of clinically significant upper gastrointestinal events with etodolac and naproxen: a historical cohort analysis. ( Cryer, B; Cung, A; Kazi, S; Kelly, KC; Little, BB; Roberts, KW; Sarosi, GA; Smith, HJ; Weideman, RA, 2004) |
| "Aspirin is a widely used drug and perceived by most physicians to be inexpensive." | 1.31 | The real cost of aspirin. ( Brooks, NH; Burgess, MI; Densem, CG; Lee, HS; Levy, RD, 2000) |
| " There was a linear dose-response curve that was steeper in women than in men." | 1.29 | Variability in the risk of major gastrointestinal complications from nonaspirin nonsteroidal anti-inflammatory drugs. ( Dobson, A; Henry, D; Turner, C, 1993) |
| "A high unit dose (15 grain/975 mg) enteric coated aspirin preparation was studied in normal individuals and patients with arthritis to determine how readily well tolerated, therapeutic (150-300 micrograms/ml) salicylate (SA) levels could be achieved using a twice daily dosing regimen." | 1.27 | Aspirin dosing using 15 grain enteric coated tablets. ( Feigal, D; Jang, H; Pollet, S; White, RH; Yim, CW, 1985) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 86 (28.20) | 18.7374 |
| 1990's | 28 (9.18) | 18.2507 |
| 2000's | 108 (35.41) | 29.6817 |
| 2010's | 80 (26.23) | 24.3611 |
| 2020's | 3 (0.98) | 2.80 |
| Authors | Studies |
|---|---|
| Sharma, M | 1 |
| Ray, SM | 1 |
| Lichtenberger, LM | 1 |
| Zhou, T | 1 |
| Gong, Y | 1 |
| Li, J | 1 |
| Wang, Y | 1 |
| Wang, X | 1 |
| Lanas, A | 22 |
| Werz, O | 1 |
| Mikhail, E | 1 |
| Lavie, CJ | 1 |
| Howden, CW | 1 |
| Scheiman, J | 3 |
| Tursi, J | 1 |
| Negovan, A | 1 |
| Iancu, M | 1 |
| Moldovan, V | 1 |
| Sàrkàny, K | 1 |
| Bataga, S | 1 |
| Mocan, S | 1 |
| Țilea, I | 1 |
| Banescu, C | 1 |
| Moore, A | 1 |
| Crossley, A | 1 |
| Ng, B | 1 |
| Phillips, L | 1 |
| Sancak, Ö | 1 |
| Rainsford, KD | 2 |
| Wen, L | 1 |
| Nekrasov, AA | 2 |
| Timoshchenko, ES | 2 |
| Petelina, IS | 1 |
| Karpukhina, EV | 2 |
| Yeomans, ND | 2 |
| Graham, DY | 4 |
| Husni, ME | 1 |
| Solomon, DH | 1 |
| Stevens, T | 1 |
| Vargo, J | 1 |
| Wang, Q | 1 |
| Wisniewski, LM | 1 |
| Wolski, KE | 1 |
| Borer, JS | 1 |
| Libby, P | 1 |
| Lincoff, AM | 1 |
| Lüscher, TF | 1 |
| Bao, W | 1 |
| Walker, C | 1 |
| Nissen, SE | 1 |
| Zhu, B | 1 |
| Zhang, W | 2 |
| Lu, Y | 1 |
| Hu, S | 1 |
| Gao, R | 1 |
| Sun, Z | 1 |
| Chen, X | 1 |
| Ma, J | 1 |
| Guo, S | 1 |
| Du, S | 1 |
| Li, P | 1 |
| Erofeeva, SG | 1 |
| van der Elst, K | 1 |
| Oortgiesen, B | 1 |
| Kruik-Kollöffel, W | 1 |
| Hoogendoorn, M | 1 |
| Hofma, S | 1 |
| van Roon, E | 1 |
| Fujita, T | 1 |
| Kutsumi, H | 1 |
| Sanuki, T | 1 |
| Hayakumo, T | 1 |
| Azuma, T | 1 |
| Lee, T | 1 |
| Lee, R | 1 |
| Baron, JA | 2 |
| Senn, S | 2 |
| Voelker, M | 5 |
| Laurora, I | 1 |
| Thielemann, W | 1 |
| Brückner, A | 1 |
| McCarthy, D | 2 |
| Sylvester, KW | 1 |
| Cheng, JW | 1 |
| Mehra, MR | 1 |
| Uemura, N | 2 |
| Sugano, K | 2 |
| Hiraishi, H | 2 |
| Shimada, K | 2 |
| Goto, S | 2 |
| Uchiyama, S | 2 |
| Okada, Y | 2 |
| Origasa, H | 2 |
| Ikeda, Y | 2 |
| Day, RO | 1 |
| Graham, GG | 1 |
| Patrono, C | 2 |
| Martín Merino, E | 1 |
| Johansson, S | 2 |
| Nagy, P | 2 |
| García Rodríguez, LA | 6 |
| Hachiken, H | 1 |
| Murai, A | 1 |
| Wada, K | 1 |
| Kuwahara, T | 1 |
| Hosomi, K | 1 |
| Takada, M | 1 |
| Angiolillo, DJ | 1 |
| Datto, C | 1 |
| Raines, S | 1 |
| Suzuki, Y | 3 |
| Yokoyama, H | 3 |
| Soeda, S | 1 |
| Tokuoka, K | 3 |
| Watanabe, M | 3 |
| Kitagawa, Y | 3 |
| Yamada, Y | 3 |
| Sakamoto, Y | 1 |
| Shimoyama, T | 1 |
| Nakagawa, S | 1 |
| Mikami, T | 1 |
| Fukuda, S | 1 |
| Sandri, A | 1 |
| Thorat, MA | 1 |
| Cuzick, J | 1 |
| Gargallo, CJ | 3 |
| Warlé-van Herwaarden, MF | 1 |
| Koffeman, AR | 1 |
| Valkhoff, VE | 2 |
| 't Jong, GW | 1 |
| Kramers, C | 1 |
| Sturkenboom, MC | 2 |
| De Smet, PA | 1 |
| Onuchina, EV | 1 |
| Mo, C | 1 |
| Sun, G | 1 |
| Wang, YZ | 1 |
| Lu, ML | 1 |
| Yang, YS | 1 |
| Roberto, G | 1 |
| Simonetti, M | 1 |
| Cricelli, C | 1 |
| Cricelli, I | 1 |
| Giustini, SE | 1 |
| Parretti, D | 1 |
| Lapi, F | 1 |
| Huang, WK | 1 |
| Tu, HT | 1 |
| See, LC | 1 |
| Sostres, C | 4 |
| Hsu, PI | 1 |
| Tsai, TJ | 1 |
| Iijima, K | 1 |
| Shimosegawa, T | 1 |
| Mohar, DS | 1 |
| Seto, AH | 1 |
| Kern, MJ | 1 |
| Chen, Z | 1 |
| Wan, J | 1 |
| Du, H | 1 |
| Su, B | 1 |
| Chen, Q | 1 |
| Rafaniello, C | 1 |
| Ferrajolo, C | 1 |
| Sullo, MG | 1 |
| Sessa, M | 1 |
| Sportiello, L | 1 |
| Balzano, A | 1 |
| Manguso, F | 1 |
| Aiezza, ML | 1 |
| Rossi, F | 1 |
| Scarpignato, C | 2 |
| Capuano, A | 1 |
| Montagnani, S | 1 |
| Tuccori, M | 1 |
| Testi, A | 1 |
| Cristofano, M | 1 |
| Corona, T | 1 |
| Salvadori, S | 1 |
| Blandizzi, C | 1 |
| Forder, S | 1 |
| Lawrence, JR | 1 |
| Baxter, GJ | 1 |
| Paterson, JR | 1 |
| Yuan, JQ | 1 |
| Yang, M | 1 |
| Threapleton, DE | 1 |
| Qi, XS | 1 |
| Ye, DQ | 1 |
| Mao, C | 1 |
| Tang, JL | 1 |
| Higgins, JP | 1 |
| Sharma, T | 1 |
| Bliden, K | 1 |
| Chaudhary, R | 1 |
| Tantry, U | 1 |
| Gurbel, PA | 2 |
| Han, Y | 1 |
| Fort, JG | 3 |
| Schofield, D | 1 |
| Tursi, JP | 1 |
| Malakar, S | 1 |
| Shiotani, A | 2 |
| Kamada, T | 2 |
| Haruma, K | 2 |
| Nema, H | 1 |
| Kato, M | 1 |
| Katsurada, T | 1 |
| Nozaki, Y | 1 |
| Yotsukura, A | 1 |
| Yoshida, I | 1 |
| Sato, K | 1 |
| Kawai, Y | 1 |
| Takagi, Y | 1 |
| Okusa, T | 1 |
| Takiguchi, S | 1 |
| Sakurai, M | 1 |
| Asaka, M | 1 |
| Bretagne, JF | 1 |
| Lisotti, A | 1 |
| Grenci, C | 1 |
| Caponi, A | 1 |
| Roda, E | 1 |
| Rostom, A | 2 |
| Moayyedi, P | 1 |
| Hunt, R | 2 |
| Björklund, L | 1 |
| Wallander, MA | 1 |
| Lesén, E | 1 |
| Steiner, TJ | 1 |
| Tournoij, E | 1 |
| Peters, RJ | 1 |
| Langenberg, M | 1 |
| Kanhai, KJ | 1 |
| Moll, FL | 1 |
| Fiorucci, S | 2 |
| de Abajo, FJ | 2 |
| Kraus, S | 1 |
| Arber, N | 2 |
| Hokimoto, S | 1 |
| Ogawa, H | 1 |
| Gargallo, C | 1 |
| Arroyo, MT | 1 |
| Ward, R | 1 |
| Pratt, S | 2 |
| Thompson, VJ | 1 |
| Elkin, EP | 1 |
| Næsdal, J | 2 |
| Sörstadius, E | 2 |
| Sidhu, R | 1 |
| Brunt, LK | 1 |
| Morley, SR | 1 |
| Sanders, DS | 1 |
| McAlindon, ME | 1 |
| Nishi, R | 1 |
| Yamanaka, Y | 1 |
| Murao, T | 1 |
| Matsumoto, H | 1 |
| Tarumi, K | 1 |
| Sakakibara, T | 1 |
| Ng, SC | 1 |
| Chan, FK | 5 |
| Kwok, CS | 1 |
| Nijjar, RS | 1 |
| Loke, YK | 1 |
| Cayla, G | 1 |
| Collet, JP | 1 |
| Silvain, J | 1 |
| Thiefin, G | 2 |
| Woimant, F | 1 |
| Montalescot, G | 1 |
| Goodyear-Smith, F | 1 |
| Shibata, T | 1 |
| Kamano, T | 1 |
| Hirata, I | 1 |
| Huang, L | 1 |
| Mackenzie, G | 1 |
| Ouyang, N | 1 |
| Sun, Y | 1 |
| Xie, G | 1 |
| Johnson, F | 1 |
| Komninou, D | 1 |
| Rigas, B | 1 |
| Windgassen, EB | 1 |
| Funtowicz, L | 1 |
| Lunsford, TN | 1 |
| Harris, LA | 1 |
| Mulvagh, SL | 1 |
| Martín de Argila de Prados, C | 1 |
| Nakamura, H | 1 |
| Yaguchi, T | 2 |
| Butalia, S | 1 |
| Leung, AA | 1 |
| Ghali, WA | 1 |
| Rabi, DM | 1 |
| Moberg, C | 1 |
| Naesdal, J | 1 |
| Svedberg, LE | 2 |
| Duchateau, D | 1 |
| Harte, N | 1 |
| Brueckner, A | 1 |
| McNeil, J | 1 |
| Tonkin, A | 1 |
| Patel, V | 1 |
| Fisher, M | 1 |
| Gessner, U | 1 |
| Plazas, MA | 1 |
| Gimeno, E | 1 |
| Muñoz-Tudurí, M | 1 |
| Arakawa, T | 1 |
| Fujiwara, Y | 1 |
| Tominaga, K | 1 |
| Watanabe, T | 1 |
| Tanigawa, T | 1 |
| Blackler, R | 1 |
| Syer, S | 1 |
| Bolla, M | 1 |
| Ongini, E | 1 |
| Wallace, JL | 2 |
| Kasprzak, M | 1 |
| Koziński, M | 1 |
| Kubica, A | 1 |
| Navarese, EP | 1 |
| Grześk, G | 1 |
| Kubica, J | 1 |
| Kuipers, EJ | 1 |
| Leung Ki, EL | 1 |
| Pogatzki-Zahn, EM | 1 |
| Schnabel, A | 1 |
| Zahn, PK | 1 |
| Scheiman, JM | 3 |
| Herlitz, J | 1 |
| Veldhuyzen van Zanten, SJ | 1 |
| Agewall, S | 1 |
| Nauclér, EC | 1 |
| Koomanan, N | 1 |
| Ko, Y | 1 |
| Yong, WP | 1 |
| Ng, R | 1 |
| Wong, YP | 1 |
| Lim, SW | 1 |
| Salim, A | 1 |
| Chan, A | 1 |
| Tanaka, M | 1 |
| Tanaka, A | 1 |
| Suemaru, K | 1 |
| Araki, H | 1 |
| Bytzer, P | 1 |
| Elkin, E | 1 |
| Bliden, KP | 1 |
| Jeong, YH | 1 |
| Shuldiner, A | 1 |
| Chai, S | 1 |
| Gesheff, T | 1 |
| Antonino, M | 1 |
| Gesheff, M | 1 |
| Zhang, Y | 1 |
| Tantry, US | 1 |
| Bjorkman, DJ | 1 |
| Simon, LS | 2 |
| Smolen, JS | 1 |
| Abramson, SB | 1 |
| Appel, G | 1 |
| Bombardier, C | 2 |
| Brater, DC | 1 |
| Breedveld, FC | 1 |
| Brune, K | 3 |
| Burmester, GR | 1 |
| Crofford, LJ | 1 |
| Dougados, M | 1 |
| DuBois, RN | 1 |
| Fitzgerald, GA | 1 |
| Frishman, W | 1 |
| Hochberg, MC | 1 |
| Kalden, JR | 1 |
| Laine, L | 3 |
| Langman, MJ | 1 |
| Prescott, SM | 1 |
| van de Putte, LB | 1 |
| Whelton, A | 2 |
| White, WB | 1 |
| Willaims, GH | 1 |
| Deeks, JJ | 1 |
| Smith, LA | 1 |
| Bradley, MD | 1 |
| Guda, N | 1 |
| Vakil, N | 1 |
| Sawhney, MS | 1 |
| Nelson, DB | 1 |
| Smout, J | 1 |
| Stansby, G | 1 |
| Relkin, NR | 1 |
| Reichman, WE | 1 |
| Orazem, J | 1 |
| McRae, T | 1 |
| Moore, N | 1 |
| Pilotto, A | 1 |
| Franceschi, M | 1 |
| Leandro, G | 1 |
| Di Mario, F | 1 |
| Laheij, RJ | 2 |
| Van Rossum, LG | 1 |
| Jansen, JB | 2 |
| Verheugt, FW | 2 |
| Rodrigo, L | 2 |
| Márquez, JL | 1 |
| Bajador, E | 2 |
| Pérez-Roldan, F | 1 |
| Cabrol, J | 1 |
| Quintero, E | 2 |
| Montoro, M | 1 |
| Gomollón, F | 1 |
| Santolaria, S | 2 |
| Lorente, S | 1 |
| Cucala, M | 1 |
| Nuevo, J | 1 |
| James, MW | 1 |
| Hawkey, CJ | 2 |
| BOYD, EM | 3 |
| Fries, JF | 2 |
| Bruce, B | 1 |
| Lisse, JR | 1 |
| Perlman, M | 1 |
| Johansson, G | 1 |
| Shoemaker, JR | 1 |
| Schechtman, J | 1 |
| Skalky, CS | 1 |
| Dixon, ME | 1 |
| Polis, AB | 1 |
| Mollen, AJ | 1 |
| Geba, GP | 1 |
| Lee, HL | 1 |
| Han, DS | 1 |
| Kim, JB | 1 |
| Park, JY | 1 |
| Sohn, JH | 1 |
| Hahm, JS | 1 |
| Ahn, YH | 1 |
| Newton, JL | 2 |
| Johns, CE | 1 |
| May, FE | 1 |
| Kimmey, MB | 2 |
| Morant, SV | 1 |
| McMahon, AD | 1 |
| Cleland, JG | 1 |
| Davey, PG | 1 |
| MacDonald, TM | 1 |
| Alvaro-Gracia, JM | 1 |
| Bao, YL | 1 |
| Perini, R | 1 |
| Tarone, RE | 1 |
| Lipworth, L | 1 |
| McLaughlin, JK | 1 |
| Czernichow, P | 1 |
| Merle, V | 1 |
| Devi, DP | 1 |
| Sushma, M | 1 |
| Guido, S | 1 |
| Weideman, RA | 1 |
| Kelly, KC | 1 |
| Kazi, S | 1 |
| Cung, A | 1 |
| Roberts, KW | 1 |
| Smith, HJ | 1 |
| Sarosi, GA | 1 |
| Little, BB | 1 |
| Cryer, B | 4 |
| Wolfe, MM | 1 |
| Goldstein, JL | 2 |
| Bello, AE | 1 |
| Spalding, W | 1 |
| Suh, S | 1 |
| Spiegel, BM | 1 |
| Chiou, CF | 1 |
| Ofman, JJ | 1 |
| Morton, JA | 1 |
| Newton, J | 1 |
| Gray, CS | 1 |
| Papatheodoridis, GV | 1 |
| Archimandritis, AJ | 1 |
| Perez-Aisa, MA | 1 |
| Feu, F | 1 |
| Ponce, J | 2 |
| Saperas, E | 1 |
| Balanzo, J | 1 |
| Almela, P | 1 |
| Navarro, JM | 1 |
| Carballo, F | 1 |
| Castro, M | 1 |
| Bolten, WW | 1 |
| Kim, JA | 1 |
| Choi, YS | 1 |
| Kim, SH | 1 |
| Raithel, M | 1 |
| Baenkler, HW | 1 |
| Naegel, A | 1 |
| Buchwald, F | 1 |
| Schultis, HW | 1 |
| Backhaus, B | 1 |
| Kimpel, S | 1 |
| Koch, H | 1 |
| Mach, K | 1 |
| Hahn, EG | 1 |
| Konturek, PC | 1 |
| Whittle, BJ | 1 |
| Williams, GW | 1 |
| van Oijen, MG | 1 |
| Huybers, S | 1 |
| Peters, WH | 1 |
| Drenth, JP | 1 |
| Vogt, W | 1 |
| Targownik, LE | 1 |
| Al-Mamfud, A | 1 |
| Vallurupalli, NG | 1 |
| Goldhaber, SZ | 1 |
| Hochman, JS | 1 |
| Shah, NR | 1 |
| Ji, KY | 1 |
| Hu, FL | 1 |
| Ferrandez, A | 1 |
| Wilcox, CM | 1 |
| Allison, J | 1 |
| Benzuly, K | 1 |
| Borum, M | 1 |
| Grosser, T | 1 |
| Ladabaum, U | 1 |
| Paulus, H | 1 |
| Regueiro, C | 1 |
| Sandler, RS | 1 |
| Simon, L | 1 |
| Biskupiak, JE | 1 |
| Brixner, DI | 1 |
| Howard, K | 1 |
| Oderda, GM | 1 |
| Bertagnolli, MM | 1 |
| Eagle, CJ | 2 |
| Zauber, AG | 2 |
| Redston, M | 1 |
| Solomon, SD | 2 |
| Kim, K | 1 |
| Tang, J | 2 |
| Rosenstein, RB | 2 |
| Wittes, J | 2 |
| Corle, D | 1 |
| Hess, TM | 1 |
| Woloj, GM | 1 |
| Boisserie, F | 1 |
| Anderson, WF | 1 |
| Viner, JL | 1 |
| Bagheri, D | 1 |
| Burn, J | 1 |
| Chung, DC | 1 |
| Dewar, T | 1 |
| Foley, TR | 1 |
| Hoffman, N | 1 |
| Macrae, F | 1 |
| Pruitt, RE | 1 |
| Saltzman, JR | 1 |
| Salzberg, B | 1 |
| Sylwestrowicz, T | 1 |
| Gordon, GB | 1 |
| Hawk, ET | 1 |
| Spicak, J | 1 |
| Rácz, I | 1 |
| Dite, P | 1 |
| Hajer, J | 1 |
| Zavoral, M | 1 |
| Lechuga, MJ | 1 |
| Gerletti, P | 1 |
| Macdonald, K | 1 |
| Bhadra, P | 1 |
| Fowler, R | 1 |
| Levin, B | 1 |
| Hernández-Díaz, S | 2 |
| Chaussade, S | 1 |
| Avouac, B | 1 |
| Vicaut, E | 1 |
| Barreales Tolosa, L | 1 |
| Curtis, SP | 1 |
| Kaur, A | 1 |
| Cannon, CP | 1 |
| Dubé, C | 1 |
| Lewin, G | 1 |
| Tsertsvadze, A | 1 |
| Barrowman, N | 1 |
| Code, C | 1 |
| Sampson, M | 1 |
| Moher, D | 1 |
| Pérez Manauta, J | 1 |
| Perez Perez, GI | 1 |
| Zhang, YH | 1 |
| Ji, H | 1 |
| Peng, SX | 1 |
| Jiménez, P | 1 |
| García, A | 1 |
| Santander, S | 1 |
| Piazuelo, E | 1 |
| Sopena, F | 1 |
| Hinz, B | 1 |
| Renner, B | 1 |
| Strand, V | 1 |
| Weinstein, WM | 1 |
| Stricker, K | 1 |
| Murphy, V | 1 |
| Richard, D | 1 |
| Krammer, G | 1 |
| Rebuli, R | 1 |
| Tseng, GY | 1 |
| Lin, HJ | 1 |
| Lessof, MH | 2 |
| Anderson, JB | 1 |
| Royer, GL | 1 |
| Seckman, CE | 1 |
| Welshman, IR | 1 |
| Robinson, DR | 1 |
| Hanks, GW | 1 |
| Ivey, KJ | 4 |
| Börsch, G | 1 |
| Schmidt, G | 1 |
| Guobis, G | 1 |
| Iushenaite, Ia | 1 |
| Tugwell, P | 1 |
| Hart, L | 1 |
| Kraag, G | 1 |
| Park, A | 1 |
| Dok, C | 1 |
| Bianchi, F | 1 |
| Goldsmith, C | 1 |
| Buchanan, WW | 1 |
| Sachdev, GK | 1 |
| Vij, JC | 1 |
| Nanda, R | 1 |
| Anand, BS | 1 |
| Ehrlich, G | 1 |
| Cupit, GC | 1 |
| Buttinoni, A | 1 |
| Tommasini, R | 1 |
| Tabata, K | 2 |
| Okabe, S | 2 |
| O'Laughlin, JC | 2 |
| Hoftiezer, JW | 2 |
| Johnson, PC | 1 |
| Maggiolo, P | 1 |
| Pfau, J | 1 |
| Klinger, J | 1 |
| Mikulaschek, WM | 1 |
| Duggan, JM | 1 |
| Fuster, V | 1 |
| Chesebro, JH | 1 |
| Huston, GJ | 1 |
| Culliton, BJ | 1 |
| Waterfall, WK | 1 |
| Côté, R | 1 |
| Battista, RN | 1 |
| Abrahamowicz, M | 1 |
| Langlois, Y | 1 |
| Bourque, F | 1 |
| Mackey, A | 1 |
| Ranke, C | 1 |
| Creutzig, A | 1 |
| Luska, G | 1 |
| Wagner, HH | 1 |
| Galanski, M | 1 |
| Bode-Böger, S | 1 |
| Frölich, J | 1 |
| Avenarius, HJ | 1 |
| Hecker, H | 1 |
| ALexander, K | 1 |
| Cappelleri, JC | 1 |
| Lau, J | 1 |
| Kupelnick, B | 1 |
| Chalmers, TC | 1 |
| Müller, P | 1 |
| Arce, L | 1 |
| Jackisch, P | 1 |
| Simon, B | 1 |
| Henry, DA | 1 |
| Ostapowicz, G | 1 |
| Robertson, J | 1 |
| Saxena, A | 1 |
| Andley, M | 1 |
| Gnanasekaran, N | 1 |
| Hassoun, S | 1 |
| Bonneau, JC | 1 |
| Drouet, M | 1 |
| Sabbah, A | 1 |
| Jauhari, J | 1 |
| Henry, D | 1 |
| Dobson, A | 1 |
| Turner, C | 1 |
| Roderick, PJ | 1 |
| Wilkes, HC | 1 |
| Meade, TW | 1 |
| Rabassa, AA | 1 |
| Goodgame, R | 1 |
| Sutton, FM | 1 |
| Ou, CN | 1 |
| Rognerud, C | 1 |
| McGoldrick, MD | 1 |
| Bailie, GR | 1 |
| Matzke, GR | 1 |
| Forbes, CD | 1 |
| Meddings, JB | 1 |
| Gibbons, I | 1 |
| Garnier, LF | 1 |
| Harker, LA | 1 |
| Boissel, JP | 1 |
| Pilgrim, AJ | 1 |
| Gent, M | 1 |
| Harewood, G | 1 |
| Tamai, Y | 1 |
| Takami, H | 1 |
| Nakahata, R | 1 |
| Ono, F | 1 |
| Munakata, A | 1 |
| Hochain, P | 1 |
| Capet, C | 1 |
| Colin, R | 1 |
| Silverstein, FE | 1 |
| Faich, G | 1 |
| Pincus, T | 1 |
| Makuch, R | 1 |
| Eisen, G | 1 |
| Agrawal, NM | 1 |
| Stenson, WF | 1 |
| Burr, AM | 1 |
| Zhao, WW | 1 |
| Kent, JD | 1 |
| Lefkowith, JB | 1 |
| Verburg, KM | 1 |
| Geis, GS | 1 |
| Burgess, MI | 1 |
| Densem, CG | 1 |
| Brooks, NH | 1 |
| Levy, RD | 1 |
| Lee, HS | 1 |
| Tramèr, MR | 1 |
| Russell, RI | 1 |
| Piqué, JM | 1 |
| Twiss, IM | 1 |
| Burggraaf, J | 1 |
| Schoemaker, RC | 1 |
| van Elburg, RM | 1 |
| den Hartigh, J | 1 |
| Cohen, AF | 1 |
| Vermeij, P | 1 |
| McCarthy, DM | 1 |
| Cleland, LG | 1 |
| James, MJ | 1 |
| Stamp, LK | 1 |
| Penglis, PS | 1 |
| Lanas A, A | 1 |
| Ferrández A, A | 1 |
| Rich, SA | 1 |
| Hunt, RH | 1 |
| Barkun, AN | 1 |
| Baron, D | 1 |
| Bursey, FR | 1 |
| Marshall, JR | 1 |
| Morgan, DG | 1 |
| Paré, P | 1 |
| Thomson, AB | 1 |
| Whittaker, JS | 1 |
| Buisseret, PD | 1 |
| Youlten, LF | 1 |
| Heinzelmann, DI | 1 |
| Sicot, C | 1 |
| Reinicke, C | 1 |
| Sherlock, P | 1 |
| Shils, ME | 1 |
| Lipkin, M | 1 |
| Winawer, SJ | 1 |
| Giansiracusa, JE | 1 |
| Donaldson, MS | 1 |
| Koonce, ML | 1 |
| Lefton, TE | 1 |
| Ruoff, GE | 1 |
| Brooks, CD | 1 |
| Vakil, BJ | 1 |
| Shah, PN | 1 |
| Dalal, NJ | 1 |
| Wagholikar, UN | 1 |
| Pispati, PK | 1 |
| Whitehouse, MW | 1 |
| Melton, JW | 1 |
| Lussier, A | 2 |
| Ward, JR | 1 |
| Neustadt, D | 1 |
| Multz, C | 1 |
| Davis, JD | 1 |
| Struth, AG | 1 |
| Turner, RA | 1 |
| Pisko, EJ | 1 |
| Ruchte, IR | 1 |
| Valtonen, EJ | 1 |
| Rosenbaum, ES | 1 |
| Barbieri, EJ | 1 |
| Ciccolunghi, SN | 1 |
| Schubiger, BI | 1 |
| Reddrop, R | 1 |
| Mehta, D | 1 |
| Mehta, S | 1 |
| Mathew, P | 1 |
| Camerlain, M | 1 |
| Menard, H | 1 |
| Myhal, D | 1 |
| Wehner, S | 1 |
| Shriver, DA | 1 |
| Dove, PA | 1 |
| White, CB | 1 |
| Sandor, A | 1 |
| Rosenthale, ME | 1 |
| Monson, RR | 1 |
| Hall, AP | 1 |
| Paton, A | 1 |
| Calhoun, W | 1 |
| Gilman, SC | 1 |
| Datko, LJ | 1 |
| Copenhaver, TW | 1 |
| Carlson, RP | 1 |
| Greene, JM | 1 |
| Winickoff, RN | 1 |
| Jones, RD | 1 |
| Baynes, RE | 1 |
| Nimitz, CT | 1 |
| Hoffman, W | 1 |
| Förster, W | 1 |
| Roth, SH | 1 |
| Hallas, J | 1 |
| Jensen, KB | 1 |
| Grodum, E | 1 |
| Damsbo, N | 1 |
| Gram, LF | 1 |
| Rubin, P | 1 |
| Yee, JP | 1 |
| Ruoff, G | 1 |
| Hennekens, CH | 1 |
| Buring, JE | 1 |
| Sandercock, P | 1 |
| Collins, R | 1 |
| Peto, R | 1 |
| Schlegel, SI | 1 |
| Paulus, HE | 1 |
| Cohen, MM | 1 |
| Kolodny, AL | 1 |
| Altman, RD | 1 |
| Butt, JH | 1 |
| Barthel, JS | 1 |
| Moore, RA | 1 |
| Riggs, BS | 1 |
| Kulig, K | 1 |
| Rumack, BH | 1 |
| Hackenthal, E | 1 |
| Altman, R | 1 |
| Catalano, MA | 1 |
| Grigor, RR | 1 |
| Spitz, PW | 1 |
| Furst, DE | 1 |
| Berkowitz, JM | 1 |
| Rogenes, PR | 1 |
| Sharp, JT | 1 |
| Warner, CW | 1 |
| Burch, FX | 1 |
| Anslow, JA | 1 |
| Balm, TK | 1 |
| Hooper, JW | 1 |
| Szego, P | 1 |
| Wagner, GS | 1 |
| Pollet, S | 1 |
| White, RH | 1 |
| Jang, H | 1 |
| Yim, CW | 1 |
| Feigal, D | 1 |
| Kinsella, TD | 1 |
| MacKenzie, KR | 1 |
| Kim, SO | 1 |
| Johnson, LG | 1 |
| Kaito, I | 1 |
| Sato, S | 1 |
| Lamphier, T | 1 |
| Rodriguez, A | 1 |
| Richards, D | 1 |
| Cuthbert, MF | 1 |
| Scalabrino, R | 1 |
| Fichera, G | 1 |
| Mirelli, E | 1 |
| Nakano, J | 1 |
| Koss, MC | 1 |
| Huskisson, EC | 2 |
| Wojtulewski, JA | 2 |
| Berry, H | 1 |
| Scott, J | 1 |
| Hart, FD | 1 |
| Balme, HW | 1 |
| Haslock, I | 1 |
| Wright, V | 1 |
| Abrahamsen, AF | 1 |
| Eika, C | 1 |
| Godal, HC | 1 |
| Lorentsen, E | 1 |
| Rubin, A | 1 |
| Chernish, SM | 1 |
| Crabtree, R | 1 |
| Gruber, CM | 1 |
| Helleberg, L | 1 |
| Rodda, BE | 1 |
| Warrick, P | 1 |
| Wolen, RL | 1 |
| Ridolfo, AS | 1 |
| Desbaillets, LG | 1 |
| Petrin, A | 1 |
| Schmidt, R | 1 |
| Berman, PM | 1 |
| Kirsner, JB | 1 |
| Dick-Smith, JB | 1 |
| Green, AY | 1 |
| Green, D | 1 |
| Huttman, DH | 1 |
| Hahn, KJ | 1 |
| Morgenstern, E | 1 |
| Weber, E | 1 |
| Iasinovskiĭ, MA | 1 |
| Ostapchuk, NA | 1 |
| Caulin, C | 1 |
| Henrard, JC | 1 |
| Meloff, K | 1 |
| Taylor, LA | 1 |
| Crawford, LM | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The Effect of Electroacupuncture (EA) on the Success of Inferior Alveolar Nerve Block (IANB) and Post-operative Pain Relief in Mandibular Molar With Symptomatic Irreversible Pulpitis (SIP) Among Malaysians: A Study Protocol for Randomized Double-Blinded C[NCT04804761] | 20 participants (Anticipated) | Interventional | 2023-01-01 | Recruiting | |||
| A Prospective Descriptive, Multi-National, Multi-Centre Observational Study of Burden of Upper GI-Symptoms in Subjects With Cardiovascular Risk or Disease Receiving Treatment With Low-Dose Aspirin[NCT00681759] | 1,836 participants (Actual) | Observational | 2008-01-31 | Completed | |||
| WilL LOWer Dose Aspirin be More Effective Following ACS? (WILLOW-ACS)[NCT02741817] | Phase 4 | 20 participants (Actual) | Interventional | 2016-06-26 | Completed | ||
| A Randomized, Double-blind, Parallel-group, Multicentre, Phase III Study to Assess the Effect of Esomeprazole 20 or 40 mg od Versus Placebo on the Occurrence of Peptic Ulcers During 26 Weeks in Subjects on Continuous Low Dose Acetylsalicylic Acid (ASA)[NCT00441727] | Phase 3 | 2,426 participants (Actual) | Interventional | 2007-02-28 | Completed | ||
| A Randomized, Open-Label, Cross-Over, Study to Evaluate the Inhibitory Effect of Clopidogrel, EC Aspirin 81 mg and EC Omeprazole 40 mg All Dosed Concomitantly and PA32540 and Clopidogrel Dosed Separately on Platelet Aggregation in Healthy Volunteers[NCT01557335] | Phase 1 | 30 participants (Actual) | Interventional | 2010-11-30 | Completed | ||
| Exploring the Health Benefits Associated With Daily Pulse Consumption in Individuals With Peripheral Arterial Disease[NCT00755677] | Early Phase 1 | 26 participants (Actual) | Interventional | 2007-03-31 | Completed | ||
| Prevention of Sporadic Colorectal Adenomas With Celecoxib[NCT00005094] | Phase 3 | 1,170 participants (Anticipated) | Interventional | 2000-03-31 | Completed | ||
| Celecoxib for the Treatment of Non-muscle Invasive Bladder Cancer[NCT02343614] | Phase 2 | 58 participants (Actual) | Interventional | 2003-03-31 | Completed | ||
| Clinical Protocol For a Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Celecoxib (SC-58635) In The Prevention of Colorectal Sporadic Adenomatous Polyps (PRESAP)[NCT00141193] | Phase 3 | 1,561 participants (Actual) | Interventional | 2001-02-28 | Completed | ||
| A Randomized, Double-Blind, Multicenter Study to Evaluate the Tolerability and Effectiveness of Etoricoxib 90 mg q.d. vs. Diclofenac Sodium 50 mg t.i.d. in Patients With Osteoarthritis[NCT00092703] | Phase 3 | 6,000 participants | Interventional | 2002-06-27 | Completed | ||
| A 12-Week, Randomized, Placebo- and Active-Comparator-Controlled, Parallel-Group, Double-Blind Study to Assess the Safety and Efficacy of Etoricoxib 30 mg Versus Ibuprofen 2400 mg in Patients With Osteoarthritis (Study 1)[NCT00269191] | Phase 3 | 528 participants (Actual) | Interventional | 2003-02-05 | Completed | ||
| A Randomized, Double-Blind, Active-Comparator-Controlled, Parallel-Group Study to Evaluate the Safety of Etoricoxib in Patients With Osteoarthritis or Rheumatoid Arthritis[NCT00250445] | Phase 3 | 23,498 participants (Actual) | Interventional | 2003-01-31 | Completed | ||
| [NCT00000491] | Phase 3 | 0 participants | Interventional | 1974-10-31 | Completed | ||
| The Effect of Resistant Starch Consumption on Zinc Hemostasis in Malawian Children at Risk for Zinc Deficiency[NCT01811836] | 20 participants (Actual) | Interventional | 2013-03-31 | Completed | |||
| GpCRC Pediatric Gastroparesis Registry 2: Characterization and Clinical Course of Symptoms and Gastric Emptying in Pediatric, Adolescent, and Young Adult Participants With Symptoms of Gastroparesis[NCT05981300] | 216 participants (Anticipated) | Observational [Patient Registry] | 2024-02-28 | Not yet recruiting | |||
| A Randomized, Double-Blind Trial to Test Higher- Versus Lower-Doses of Aspirin on Inflammatory Markers and Platelet Biomarkers and Nitric Oxide Formation in High Risk Primary Prevention (Patients With Metabolic Syndrome)[NCT00272311] | Phase 4 | 70 participants (Actual) | Interventional | 2006-10-31 | Completed | ||
| A Randomized, Double-Blind Trial to Test Higher- Versus Lower-Doses of Aspirin on Inflammatory Markers and Platelet Biomarkers and Nitric Oxide Formation & Endothelial Function in Secondary Prevention (Pts w/Chronic Stable Coronary Disease)[NCT00272337] | Phase 4 | 37 participants (Actual) | Interventional | 2006-10-31 | Completed | ||
| Effect of a Cold Water Immersion (CWI) on Pain in People With Gouty Arthritis: A Community Based Randomized Controlled Trial[NCT04587544] | 76 participants (Actual) | Interventional | 2019-07-01 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
RDQ contains 12 items on a 6-point Likert scale. Six items concern the frequence ('Did not have' to 'Daily') and six items concern the severity ('Did not have' to 'Severe'). The dyspepsia dimension contains the items 'Burning feeling in the center of the upper stomach' and 'Pain in the center of the upper stomach'. Best score possible 0, worst score possible - daily occurrence. (NCT00441727)
Timeframe: RDQ was assessed at baseline, 8 weeks, 16 week, 26 weeks or upon withdrawal.
| Intervention | participants (Number) |
|---|---|
| Esomeprazole 40 mg | 591 |
| Esomeprazole 20 mg | 577 |
| Placbo | 504 |
RDQ contains 12 items on a 6-point Likert scale. Six items concern the frequency ('Did not have' to 'Daily') and six items concern the severity ('Did not have' to 'Severe'). Gastroesophageal reflux disease (GERD) items: 'Acid taste in the mouth', 'Unpleasant movement of materials upward from the stomach', 'Burning feeling behind the breastbone' and 'Pain behind the breastbone'. Best score possible 0, worst score possible - daily occurrence. (NCT00441727)
Timeframe: RDQ was assessed at baseline, 8 weeks, 16 week, 26 weeks or upon withdrawal.
| Intervention | participants (Number) |
|---|---|
| Esomeprazole 40 mg | 554 |
| Esomeproazole 20 mg | 537 |
| Placebo | 451 |
(NCT00441727)
Timeframe: The number of erosions was determined by endoscopy performed at baseline, 8 weeks and 26 weeks or upon withdrawal.
| Intervention | participants (Number) |
|---|---|
| Esomeprazole 40 | 214 |
| Esomeproazole 20 | 213 |
| Placebo | 380 |
The occurrence of gastric ulcer (mucosal break measuring >= 3 mm over its largest diameter with a sharply demarcated margin) was determined by endoscopy performed at baseline, 8 weeks and 26 weeks or upon withdrawal. (NCT00441727)
Timeframe: During 26 weeks
| Intervention | percentage of participants (Number) |
|---|---|
| Esomeprazole 40 | 1.1 |
| Esomeproazole 20 | 0.75 |
| Placebo | 4.1 |
The occurrence of ulcer (mucosal break measuring >= 3 mm over its largest diameter with a sharply demarcated margin) was determined by endoscopy performed at baseline, 8 weeks and 26 weeks or upon withdrawal. (NCT00441727)
Timeframe: During 26 weeks
| Intervention | percentage of participants (Number) |
|---|---|
| Esomeprazole 40 | 1.35 |
| Esomeproazole 20 | 1 |
| Placebo | 6.58 |
The occurrence of duodenal ulcer (mucosal break measuring >= 3 mm over its largest diameter with a sharply demarcated margin) was determined by endoscopy performed at baseline, 8 weeks and 26 weeks or upon withdrawal. (NCT00441727)
Timeframe: During 26 weeks
| Intervention | percentage of participants (Number) |
|---|---|
| Esomeprazole 40 | 0.24 |
| Esomeproazole 20 | 0.25 |
| Placebo | 2.73 |
Changes in Heme oxygenase (HO-1) a downstream target of nitric oxide (NO) formation. (NCT00272311)
Timeframe: Baseline to 3 Months (90-97 days)
| Intervention | ng/mL (Mean) |
|---|---|
| Arm 1 of 5 Randomized Treatment Arms | 27.6 |
| Arm 2 of 5 Randomized Treatment Arms | 27.0 |
| Arm 3 of 5 Randomized Treatment Arms | 31.4 |
| Arm 4 of 5 Randomized Treatment Arms | 25.7 |
| Arm 5 of 5 Randomized Treatment Arms | 28.3 |
Heme oxygenase a downstream target of nitric oxide formation (NCT00272337)
Timeframe: Baseline to 3 Months (90-97 days)
| Intervention | ng/mL (Mean) |
|---|---|
| 1 of 5 Randomized Treatment Arms | 10.0 |
| 2 of 5 Randomized Treatment Arms | 11.2 |
| 3 of 5 Randomized Treatment Arms | 10.0 |
| 4 of 5 Randomized Treatment Arms | 11.0 |
| 5 of 5 Randomized Treatment Arms | 9.6 |
119 reviews available for aspirin and Cholera Infantum
| Article | Year |
|---|---|
Comparison of gastrointestinal adverse events between fast release tablets and regular acetylsalicylic acid (aspirin) galenics after short-term use: a meta-analysis of randomized clinical trials.
Topics: Aspirin; Gastrointestinal Diseases; Humans; Randomized Controlled Trials as Topic; Tablets | 2023 |
Upper Gastrointestinal Toxicity Associated With Long-Term Aspirin Therapy: Consequences and Prevention.
Topics: Aspirin; Cardiovascular Diseases; Gastrointestinal Diseases; Gastrointestinal Tract; Global Health; | 2017 |
[Proton pump inhibitors when using clopidogrel: balance between necessity and disadvantages].
Topics: Aspirin; Clopidogrel; Drug Interactions; Female; Gastrointestinal Diseases; Gastrointestinal Hemorrh | 2019 |
Adherence to the preventive strategies for nonsteroidal anti-inflammatory drug- or low-dose aspirin-induced gastrointestinal injuries.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Drug Prescriptions; Gastrointestinal Diseases; Gui | 2013 |
Gastrointestinal adverse effects of short-term aspirin use: a meta-analysis of published randomized controlled trials.
Topics: Abdominal Pain; Aspirin; Gastrointestinal Diseases; Humans; Randomized Controlled Trials as Topic; T | 2013 |
Esomeprazole and aspirin fixed combination for the prevention of cardiovascular events.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Cost-Benefit Analysis; Drug Combin | 2013 |
Low-dose aspirin in primary prevention: cardioprotection, chemoprevention, both, or neither?
Topics: Anticarcinogenic Agents; Aspirin; Cardiovascular Diseases; Cyclooxygenase 1; Cyclooxygenase 2; Epide | 2013 |
Prophylactic use of aspirin: systematic review of harms and approaches to mitigation in the general population.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Female; Gastrointestinal Diseases; Gastroin | 2015 |
Management of low-dose aspirin and clopidogrel in clinical practice: a gastrointestinal perspective.
Topics: Aspirin; Cardiovascular Diseases; Clopidogrel; Dose-Response Relationship, Drug; Drug Therapy, Combi | 2015 |
[Antiplatelet therapy with acetylsalicylic acid: approaches to reducing the frequency of gastrointenstinal adverse reactions].
Topics: Aspirin; Cardiovascular Diseases; Gastrointestinal Diseases; Humans; Platelet Aggregation Inhibitors | 2014 |
PPI versus Histamine H2 Receptor Antagonists for Prevention of Upper Gastrointestinal Injury Associated with Low-Dose Aspirin: Systematic Review and Meta-analysis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Aspirin; Gastrointestinal Diseases; Hemo | 2015 |
Aspirin Use on Incidence and Mortality of Gastrointestinal Cancers: Current State of Epidemiological Evidence.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Colorectal Neopl | 2015 |
Epidemiology of Low Dose Aspirin Damage in the Lower Gastrointestinal Tract.
Topics: Animals; Aspirin; Cardiovascular Diseases; Dose-Response Relationship, Drug; Endoscopy, Gastrointest | 2015 |
Risk Factors for Upper GI Damage in Low-Dose Aspirin Users and the Interaction Between H. pylori Infection and Low-Dose Aspirin Use.
Topics: Animals; Aspirin; Dose-Response Relationship, Drug; Gastrointestinal Diseases; Helicobacter Infectio | 2015 |
Cardiovascular Effects of Nonsteroidal Anti-inflammatory Drugs.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Cyclooxygenase 2 Inhibito | 2016 |
Gastrointestinal Safety of Aspirin for a High-Dose, Multiple-Day Treatment Regimen: A Meta-Analysis of Three Randomized Controlled Trials.
Topics: Abdominal Pain; Adolescent; Adult; Aged; Aged, 80 and over; Aspirin; Female; Gastrointestinal Diseas | 2016 |
Systematic review with meta-analysis: the gastrointestinal benefits of COX-2 selective inhibitors with concomitant use of low-dose aspirin.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cyclooxygenase 2 Inhibitors; Gastrointestinal Dise | 2016 |
Efficacy of aspirin (325 mg) + omeprazole (40 mg) in treating coronary artery disease.
Topics: Aspirin; Cardiovascular Diseases; Coronary Artery Disease; Gastrointestinal Diseases; Gastrointestin | 2017 |
Bioactive food chemicals and gastrointestinal symptoms: a focus of salicylates.
Topics: Aspirin; Basophils; Food Analysis; Food Hypersensitivity; Gastrointestinal Diseases; Humans; Immunol | 2017 |
Low-dose aspirin-induced gastrointestinal diseases: past, present, and future.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Dose-Response Relationship, Drug; Gastrointestinal | 2008 |
Aspirin in cardiology--benefits and risks.
Topics: Adult; Aged; Aspirin; Brain Ischemia; Cerebral Hemorrhage; Female; Gastrointestinal Diseases; Humans | 2009 |
Gastrointestinal tolerability of aspirin and the choice of over-the-counter analgesia for short-lasting acute pain.
Topics: Acute Disease; Adolescent; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cross-Over | 2009 |
Prevention of nonsteroidal anti-inflammatory drug-induced ulcer: looking to the future.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Cyclooxygenase 2 Inhibito | 2009 |
[Antiplatelet therapy and gastrointestinal complications].
Topics: Aspirin; Cardiovascular Diseases; Gastrointestinal Diseases; Humans; Platelet Aggregation Inhibitors | 2009 |
Drug-related damage of the ageing gastrointestinal tract.
Topics: Age Factors; Aged; Aged, 80 and over; Aging; Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-St | 2009 |
Adverse effects of non-steroidal anti-inflammatory drugs (NSAIDs, aspirin and coxibs) on upper gastrointestinal tract.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cyclooxygenase 2 Inhibitors; Cytoprotection; Gastr | 2010 |
Identifying and assessing benefit-risk in primary care--a family physician's perspective.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Aspirin; Cardiovascular Diseases; Drug Interacti | 2010 |
Gastrointestinal bleeding associated with low-dose aspirin use: relevance and management in clinical practice.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Dose-Response Relationship, Drug; Gastrointestinal | 2011 |
NSAID-induced gastrointestinal and cardiovascular injury.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Clopidogrel; Cyc | 2010 |
Effects of proton pump inhibitors on adverse gastrointestinal events in patients receiving clopidogrel: systematic review and meta-analysis.
Topics: Aspirin; Clopidogrel; Drug Interactions; Drug Therapy, Combination; Gastrointestinal Diseases; Human | 2011 |
[Low-dose aspirin induced intestinal damage -including the influence of low-dose aspirin to existing lesions-].
Topics: Animals; Aspirin; Capsule Endoscopy; Cerebrovascular Disorders; Cyclooxygenase Inhibitors; Gastroint | 2010 |
C-reactive protein and high-sensitivity C-reactive protein: an update for clinicians.
Topics: Aspirin; Biomarkers; C-Reactive Protein; Cardiovascular Diseases; Communicable Diseases; Gastrointes | 2011 |
Aspirin effect on the incidence of major adverse cardiovascular events in patients with diabetes mellitus: a systematic review and meta-analysis.
Topics: Aspirin; Cardiovascular Agents; Cardiovascular Diseases; Diabetes Complications; Evidence-Based Medi | 2011 |
Short-term acetylsalicylic acid (aspirin) use for pain, fever, or colds - gastrointestinal adverse effects: a meta-analysis of randomized clinical trials.
Topics: Acetaminophen; Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Common Cold; Double-Blind Me | 2011 |
Gastrointestinal effects of the addition of ascorbic acid to aspirin.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antioxidants; Ascorbic Acid; Aspirin; Drug-Related Side Eff | 2012 |
[Pathophysiology and treatment of drug-induced injury in gastrointestinal tract].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Gastric Mucosa; Gastrointestinal Diseases; Gastroi | 2011 |
[An overview of methods dedicated to protection of the digestive tract in patients treated with aspirin. Focus on clinical effectiveness and antiplatelet properties].
Topics: Aspirin; Drug Therapy, Combination; Gastrointestinal Diseases; Gastrointestinal Tract; Humans; Plate | 2012 |
Gastrointestinal lesions and complications of low-dose aspirin in the gastrointestinal tract.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Gastrointestinal Diseases; Gastrointestinal Hemorr | 2012 |
Risk factors for gastrointestinal bleeding associated with low-dose aspirin.
Topics: Age Factors; Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Aspirin; Cardiovascular Diseas | 2012 |
Room for improvement: unmet needs in postoperative pain management.
Topics: Analgesics, Non-Narcotic; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; | 2012 |
One hundred years of NSAID gastropathy: are coxibs the answer?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cyclooxygenase Inhibitors; Gastrointestinal Diseas | 2001 |
Controversies in COX-2 selective inhibition.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Aspirin; Cyclooxygenase Inhibitors; | 2002 |
Efficacy, tolerability, and upper gastrointestinal safety of celecoxib for treatment of osteoarthritis and rheumatoid arthritis: systematic review of randomised controlled trials.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Aspirin; Celecoxib; Cyclooxygenase I | 2002 |
Forty years of ibuprofen use.
Topics: Acetaminophen; Analgesics, Non-Narcotic; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Gastroint | 2003 |
Assessment of non-steroidal anti-inflammatory drug (NSAID) damage in the human gastrointestinal tract.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyc | 2003 |
Review article: the ageing bowel and intolerance to aspirin.
Topics: Age Factors; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Forecasting; Gastrointestinal Disease | 2004 |
Review article: appropriate use of proton pump inhibitors with traditional nonsteroidal anti-inflammatory drugs and COX-2 selective inhibitors.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyc | 2004 |
Safety of anti-inflammatory treatment--new ways of thinking.
Topics: Acetates; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cyclooxygenase 1; Cyclooxygenase 2; Cycl | 2004 |
Licofelone--clinical update on a novel LOX/COX inhibitor for the treatment of osteoarthritis.
Topics: Acetates; Aspirin; Celecoxib; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclo | 2004 |
Mechanisms of nonsteroidal anti-inflammatory drug-induced gastrointestinal injury and repair: a window of opportunity for cyclooxygenase-inhibiting nitric oxide donors.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Celecoxib; Cyclooxygenase 1; Cyclooxygenase 2; Cyc | 2004 |
Review article: prevention of non-steroidal anti-inflammatory drug gastrointestinal complications--review and recommendations based on risk assessment.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Aspirin; Cyclooxygenase 2; Decision Maki | 2004 |
[Epidemiology of digestive complications associated with use of low-dose aspirin].
Topics: Aspirin; Gastrointestinal Diseases; Helicobacter Infections; Helicobacter pylori; Humans; Risk Facto | 2004 |
Cardioprotective effects and gastrointestinal risks of aspirin: maintaining the delicate balance.
Topics: Aged; Anti-Ulcer Agents; Aspirin; Cardiovascular Diseases; Dose-Response Relationship, Drug; Drug Ad | 2004 |
Minimizing complications from nonsteroidal antiinflammatory drugs: cost-effectiveness of competing strategies in varying risk groups.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Aspirin | 2005 |
Role of Helicobacter pylori eradication in aspirin or non-steroidal anti-inflammatory drug users.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Gastrointestinal Diseases; Helicobacter Infections | 2005 |
[Recommendations for treatment with nonsteroidal anti-inflammatory drugs].
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Aspirin; Cardiovascular Disease | 2005 |
Nitric oxide-modulating agents for gastrointestinal disorders.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Enteritis; Esophagus; Fissure in Ano; Gas | 2005 |
An update on nonsteroidal anti-inflammatory drugs and cyclooxygenase-2 inhibitors.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Cyclooxygenase 2 Inhibito | 2005 |
[Gastroenterology in the elderly].
Topics: Abdominal Pain; Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Anti-Inflammatory Agents, N | 2005 |
Gastrointestinal complications of dual antiplatelet therapy.
Topics: Aspirin; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; Duodenal Ulcer; Endoscopy, | 2006 |
Interaction or relationship between Helicobacter pylori and non-steroidal anti-inflammatory drugs in upper gastrointestinal diseases.
Topics: Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Aspirin; Cardiova | 2006 |
NSAID-induced gastrointestinal damage: current clinical management and recommendations for prevention.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cyclooxygenase 2 Inhibitors; Drug Combinations; Dy | 2006 |
Unmet needs in non-steroidal anti-inflammatory drug-induced upper gastrointestinal diseases.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Cyclooxygenase 2 Inhibito | 2006 |
Management of high-risk patients on non-steroidal anti-inflammatory drugs or aspirin.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Gastrointestinal Diseases | 2006 |
Review article: gastrointestinal bleeding with low-dose aspirin - what's the risk?
Topics: Adrenal Cortex Hormones; Aging; Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Aspirin; Ca | 2006 |
Primer: managing NSAID-induced ulcer complications--balancing gastrointestinal and cardiovascular risks.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Contraindications; Cycloo | 2006 |
[What is the impact of cardiovascular and renal complications on the benefit/risk ratio of the NSAIDs?].
Topics: Age Factors; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Contro | 2006 |
Low-dose aspirin and upper gastrointestinal damage: epidemiology, prevention and treatment.
Topics: Anti-Ulcer Agents; Aspirin; Gastrointestinal Diseases; Helicobacter Infections; Helicobacter pylori; | 2007 |
Assessment of upper gastrointestinal safety of etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Arthritis, Rheumatoid; Aspirin; Cyclooxyge | 2007 |
Assessment of upper gastrointestinal safety of etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Arthritis, Rheumatoid; Aspirin; Cyclooxyge | 2007 |
Assessment of upper gastrointestinal safety of etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Arthritis, Rheumatoid; Aspirin; Cyclooxyge | 2007 |
Assessment of upper gastrointestinal safety of etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Arthritis, Rheumatoid; Aspirin; Cyclooxyge | 2007 |
Assessment of upper gastrointestinal safety of etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Arthritis, Rheumatoid; Aspirin; Cyclooxyge | 2007 |
Assessment of upper gastrointestinal safety of etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Arthritis, Rheumatoid; Aspirin; Cyclooxyge | 2007 |
Assessment of upper gastrointestinal safety of etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Arthritis, Rheumatoid; Aspirin; Cyclooxyge | 2007 |
Assessment of upper gastrointestinal safety of etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Arthritis, Rheumatoid; Aspirin; Cyclooxyge | 2007 |
Assessment of upper gastrointestinal safety of etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Arthritis, Rheumatoid; Aspirin; Cyclooxyge | 2007 |
The use of aspirin for primary prevention of colorectal cancer: a systematic review prepared for the U.S. Preventive Services Task Force.
Topics: Adenoma; Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Colonic P | 2007 |
[Gastropathy by NSAID].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Gastrointestinal Diseases; Histamine H2 Antagonist | 2005 |
[When and why should we eradicate the Helicobacter pylori?].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Gastrointestinal Diseases; Histamine H2 Antagonist | 2005 |
[A novel class of anti-inflammatory and analgesic drugs--NO-donating NSAIDs].
Topics: Acetaminophen; Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiotonic Agents; Cycloo | 2007 |
Routine aspirin or nonsteroidal anti-inflammatory drugs for the primary prevention of colorectal cancer: recommendation statement.
Topics: Adenoma; Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Colonic Polyps; Colorectal Neoplas | 2007 |
Prevention of cancer in the upper gastrointestinal tract with COX-inhibition. Still an option?
Topics: Adenocarcinoma; Anticarcinogenic Agents; Aspirin; Cardiovascular Diseases; Cell Transformation, Neop | 2007 |
How to advise aspirin use in patients who need NSAIDs.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Cyclooxygenase 2 Inhibito | 2007 |
Strategies to reduce the GI risks of antiplatelet therapy.
Topics: Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Aspirin; Cardiova | 2005 |
Drug insight: cyclo-oxygenase-2 inhibitors--a critical appraisal.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma; Cardiovascular Diseases; Cyclooxygenase 2 | 2007 |
Improving the gastrointestinal tolerability of aspirin in older people.
Topics: Aged; Aspirin; Gastrointestinal Diseases; Humans; Peptic Ulcer | 2006 |
Are COX-2 inhibitors preferable to non-selective non-steroidal anti-inflammatory drugs in patients with risk of cardiovascular events taking low-dose aspirin?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Cyclooxygenase Inhibitors | 2007 |
Prostaglandins and other mediators in food intolerance.
Topics: Arachidonic Acid; Arachidonic Acids; Aspirin; Autacoids; Chemotactic Factors; Cyclooxygenase Inhibit | 1984 |
Prostaglandins and anti-inflammatory drugs.
Topics: Animals; Anti-Inflammatory Agents; Aspirin; Central Nervous System Diseases; Cyclic AMP; Drug Hypers | 1983 |
Nonprescription analgesics.
Topics: Acetaminophen; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Chemical and Drug Induced Liver Inj | 1983 |
Gastrointestinal effects of antipyretic analgesics.
Topics: Acetaminophen; Adenosine Triphosphate; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Bicarbonate | 1983 |
[Drug-induced lesions in the upper gastrointestinal tract].
Topics: Adrenal Cortex Hormones; Anti-Bacterial Agents; Arthritis, Rheumatoid; Aspirin; Cheilitis; Drug-Rela | 1984 |
[Pharmacodynamics and adverse effects of modern nonsteroid anti-inflammatory agents].
Topics: Adult; Anti-Inflammatory Agents; Arthritis, Rheumatoid; Aspirin; Clinical Trials as Topic; Diclofena | 1981 |
The use of non-prescription analgesics in an older population.
Topics: Acetaminophen; Aged; Analgesics; Aspirin; Blood Coagulation; Chemical and Drug Induced Liver Injury; | 1982 |
Gastrointestinal toxicity of minor analgesics.
Topics: Analgesics; Anti-Inflammatory Agents; Aspirin; Blood Platelets; Caffeine; Drug Combinations; Gastroi | 1980 |
10. Antithrombotic therapy: role of platelet-inhibitor drugs. II. Pharmacologic effects of platelet-inhibitor drugs (second of three parts).
Topics: Aspirin; Dipyridamole; Drug Therapy, Combination; Epoprostenol; Fibrinolytic Agents; Gastrointestina | 1981 |
Efficacy and safety of different aspirin dosages on vascular diseases in high-risk patients. A metaregression analysis.
Topics: Aspirin; Cerebral Hemorrhage; Cerebrovascular Disorders; Dose-Response Relationship, Drug; Gastroint | 1995 |
Drugs as a cause of gastrointestinal disease.
Topics: Adrenal Cortex Hormones; Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Ca | 1994 |
The gastrointestinal toxicity of aspirin: an overview of randomised controlled trials.
Topics: Aged; Aspirin; Cardiovascular Diseases; Digestive System; Female; Gastrointestinal Diseases; Gastroi | 1993 |
Nonnarcotic analgesics: prevalence and estimated economic impact of toxicities.
Topics: Acetaminophen; Analgesics, Non-Narcotic; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Chemical | 1997 |
Which prophylactic aspirin?
Topics: Aspirin; Chemistry, Pharmaceutical; Delayed-Action Preparations; Gastrointestinal Diseases; Humans; | 1997 |
[Aspirin in secondary cardiovascular prevention: from clinical studies to daily practice].
Topics: Aspirin; Circadian Rhythm; Gastrointestinal Diseases; Humans; Myocardial Infarction; Platelet Aggreg | 1997 |
[Digestive complications of aspirin].
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cyclooxygenase Inhibitors; Digestive System; | 2000 |
Non-steroidal anti-inflammatory drugs and gastrointestinal damage-problems and solutions.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Aspirin; Cyclooxygenase Inhibitors | 2001 |
[Digestive toxicity of low-dose aspirin: an underestimated and unresolved problem].
Topics: Aspirin; Cardiovascular Diseases; Gastrointestinal Diseases; Humans | 2001 |
Nonsteroidal anti-inflammatory drugs, low-dose aspirin, and potential ways of reducing the risk of complications.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Clinical Trials as Topic; Disease Models, | 2001 |
Prevention and treatment of gastrointestinal symptoms and complications due to NSAIDs.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Aspirin; Gastrointestinal Diseases; Hist | 2001 |
COX-2 inhibition and thrombotic tendency: a need for surveillance.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Aspirin; Celecoxib; Cyclooxygenase I | 2001 |
Association between aspirin and upper gastrointestinal complications: systematic review of epidemiologic studies.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Case-Control Studies; Cohort Studies; Dose-Respons | 2001 |
[Should coronary patients chronically taking a low-dose of aspirin receive gastroprotective agents?].
Topics: Aspirin; Coronary Disease; Gastrointestinal Diseases; Humans | 2001 |
Recommendations for the appropriate use of anti-inflammatory drugs in the era of the coxibs: defining the role of gastroprotective agents.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Aspirin; Cyclooxygenase Inhibitors; Dose | 2002 |
[Digestive complications of corticoid treatment].
Topics: Adrenal Cortex Hormones; Adrenocorticotropic Hormone; Aspirin; Colonic Diseases; Duodenal Ulcer; Eso | 1975 |
Side-effects of anti-inflammatory drugs: are they essential or can they be circumvented?
Topics: Abnormalities, Drug-Induced; Animals; Anti-Inflammatory Agents; Aspirin; Drug Evaluation, Preclinica | 1977 |
Cost-conscious prescribing of nonsteroidal anti-inflammatory drugs for adults with arthritis. A review and suggestions.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Arthritis; Aspirin; Clinical Prot | 1992 |
Aspirin, salicylates, and nonsteroidal anti-inflammatory drugs: new class labeling and medical practice.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Drug Labeling; Gastrointestinal Diseases; Humans; | 1991 |
Aspirin and other antiplatelet agents in the secondary and primary prevention of cardiovascular disease.
Topics: Aspirin; Biomechanical Phenomena; Cardiovascular Diseases; Gastrointestinal Diseases; Humans; Myocar | 1989 |
Aspirin and other antiplatelet agents in the secondary and primary prevention of cardiovascular disease.
Topics: Aspirin; Biomechanical Phenomena; Cardiovascular Diseases; Gastrointestinal Diseases; Humans; Myocar | 1989 |
Aspirin and other antiplatelet agents in the secondary and primary prevention of cardiovascular disease.
Topics: Aspirin; Biomechanical Phenomena; Cardiovascular Diseases; Gastrointestinal Diseases; Humans; Myocar | 1989 |
Aspirin and other antiplatelet agents in the secondary and primary prevention of cardiovascular disease.
Topics: Aspirin; Biomechanical Phenomena; Cardiovascular Diseases; Gastrointestinal Diseases; Humans; Myocar | 1989 |
Non-steroidal and analgesic therapy in the elderly.
Topics: Acetaminophen; Aged; Analgesics; Analgesics, Opioid; Anti-Inflammatory Agents; Apazone; Aspirin; Cen | 1986 |
Mechanisms of nonsteroidal anti-inflammatory drug-induced gastric damage. Actions of therapeutic agents.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Gastrointestinal Diseases; Gastrointestinal Hemorr | 1988 |
Aspirin-induced gastroduodenal injury and its prevention by prostaglandins.
Topics: Animals; Aspirin; Gastric Mucosa; Gastrointestinal Diseases; Humans; Intestinal Mucosa; Prostaglandi | 1988 |
Salicylates in the treatment of arthritic disease. How safe and effective?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Aspirin; Cell Aggregation; Gastrointestinal Dise | 1988 |
Clinical spectrum of the upper gastrointestinal effects of nonsteroidal anti-inflammatory drugs. Natural history, symptomatology, and significance.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Gastrointestinal Diseases; Gastrointestinal Hemorr | 1988 |
Current status of aspirin and acetaminophen intoxication.
Topics: Acetaminophen; Aspirin; Chemical and Drug Induced Liver Injury; Gastrointestinal Diseases; Humans; R | 1987 |
[The digestive system].
Topics: Anemia, Pernicious; Antibodies; Aspirin; Feces; Galactosidases; gamma-Globulins; Gastric Juice; Gast | 1969 |
Pathophysiologic roles of prostaglandins and the action of aspirin-like drugs.
Topics: Analgesics; Animals; Aspirin; Cardiovascular System; Cats; Central Nervous System; Diarrhea; Digesti | 1973 |
The gut and arthritis.
Topics: Adrenal Cortex Hormones; Analgesics; Anti-Inflammatory Agents; Arthritis, Infectious; Arthritis, Rhe | 1974 |
Gastric mucosal injury by anti-inflammatory drugs.
Topics: Acute Disease; Anti-Inflammatory Agents; Aspirin; Chronic Disease; Epithelial Cells; Epithelium; Gas | 1974 |
51 trials available for aspirin and Cholera Infantum
| Article | Year |
|---|---|
Efficacy and safety of rivaroxaban plus clopidogrel versus aspirin plus clopidogrel in patients with coronary atherosclerotic heart disease and gastrointestinal disease undergoing percutaneous coronary intervention: study protocol for a non-inferiority ra
Topics: Aspirin; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; Gastrointestinal Diseases; | 2023 |
Randomised clinical trial: gastrointestinal events in arthritis patients treated with celecoxib, ibuprofen or naproxen in the PRECISION trial.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Arthritis, Rheumatoid; Aspi | 2018 |
Impact of concomitant low-dose aspirin on the safety and tolerability of naproxen and esomeprazole magnesium delayed-release tablets in patients requiring chronic nonsteroidal anti-inflammatory drug therapy: an analysis from 5 Phase III studies.
Topics: Adolescent; Adult; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Arthritis, Rheumatoid | 2014 |
Esomeprazole for prevention and resolution of upper gastrointestinal symptoms in patients treated with low-dose acetylsalicylic acid for cardiovascular protection: the OBERON trial.
Topics: Age Factors; Aged; Anti-Ulcer Agents; Aspirin; Cardiovascular Diseases; Dose-Response Relationship, | 2013 |
Burden of upper gastrointestinal symptoms in patients receiving low-dose acetylsalicylic acid for cardiovascular risk management: a prospective observational study.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Female; Gastrointestinal Diseases; | 2013 |
Spaced administration of PA32540 and clopidogrel results in greater platelet inhibition than synchronous administration of enteric-coated aspirin and enteric-coated omeprazole and clopidogrel.
Topics: Administration, Oral; Adult; Aspirin; Clopidogrel; Coronary Thrombosis; Cross-Over Studies; Dose-Res | 2013 |
A large, community-based, open-label trial of donepezil in the treatment of Alzheimer's disease.
Topics: Adult; Aged; Aged, 80 and over; Alzheimer Disease; Anti-Inflammatory Agents, Non-Steroidal; Antidepr | 2003 |
Forty years of ibuprofen use.
Topics: Acetaminophen; Analgesics, Non-Narcotic; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Gastroint | 2003 |
Proton-pump inhibitor therapy for acetylsalicylic acid associated upper gastrointestinal symptoms: a randomized placebo-controlled trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; | 2003 |
Gastrointestinal tolerability and effectiveness of rofecoxib versus naproxen in the treatment of osteoarthritis: a randomized, controlled trial.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Cyclooxygenase Inhibitors | 2003 |
Cyclooxygenase-2 specific inhibitors and upper gastrointestinal tolerability in patients with osteoarthritis receiving concomitant low dose aspirin: pooled analysis of 2 trials.
Topics: Aspirin; Celecoxib; Cyclooxygenase Inhibitors; Dose-Response Relationship, Drug; Double-Blind Method | 2005 |
Significance of salicylate intolerance in diseases of the lower gastrointestinal tract.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Colitis, Ulcerative; Crohn Disease; Diet; Drug Hyp | 2005 |
Celecoxib for the prevention of sporadic colorectal adenomas.
Topics: Adenoma; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovas | 2006 |
Celecoxib for the prevention of sporadic colorectal adenomas.
Topics: Adenoma; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovas | 2006 |
Celecoxib for the prevention of sporadic colorectal adenomas.
Topics: Adenoma; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovas | 2006 |
Celecoxib for the prevention of sporadic colorectal adenomas.
Topics: Adenoma; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovas | 2006 |
Celecoxib for the prevention of colorectal adenomatous polyps.
Topics: Adenoma; Adenomatous Polyps; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal | 2006 |
Celecoxib for the prevention of colorectal adenomatous polyps.
Topics: Adenoma; Adenomatous Polyps; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal | 2006 |
Celecoxib for the prevention of colorectal adenomatous polyps.
Topics: Adenoma; Adenomatous Polyps; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal | 2006 |
Celecoxib for the prevention of colorectal adenomatous polyps.
Topics: Adenoma; Adenomatous Polyps; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal | 2006 |
Clinical trial: comparison of the gastrointestinal safety of lumiracoxib with traditional nonselective nonsteroidal anti-inflammatory drugs early after the initiation of treatment--findings from the Therapeutic Arthritis Research and Gastrointestinal Even
Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Aspirin; Cyclooxygenase | 2008 |
Safety profile: fifteen years of clinical experience with ibuprofen.
Topics: Anti-Inflammatory Agents; Aspirin; Blood Cell Count; Blood Coagulation Tests; Blood Proteins; Centra | 1984 |
[Pharmacodynamics and adverse effects of modern nonsteroid anti-inflammatory agents].
Topics: Adult; Anti-Inflammatory Agents; Arthritis, Rheumatoid; Aspirin; Clinical Trials as Topic; Diclofena | 1981 |
Long-term safety of benoxaprofen.
Topics: Aged; Anti-Inflammatory Agents; Arthritis, Rheumatoid; Aspirin; Benzoxazoles; Blood Urea Nitrogen; C | 1980 |
Effects of 24 hours of aspirin, Bufferin, paracetamol and placebo on normal human gastroduodenal mucosa.
Topics: Acetaminophen; Adult; Aspirin; Buffers; Duodenum; Gastric Mucosa; Gastrointestinal Diseases; Humans; | 1982 |
The aspirin myocardial infarction study: final results. The Aspirin Myocardial Infarction Study research group.
Topics: Aspirin; Cardiovascular Diseases; Female; Follow-Up Studies; Gastrointestinal Diseases; Humans; Male | 1980 |
Lack of effect of aspirin in asymptomatic patients with carotid bruits and substantial carotid narrowing. The Asymptomatic Cervical Bruit Study Group.
Topics: Aged; Aspirin; Brain Ischemia; Carotid Arteries; Carotid Stenosis; Double-Blind Method; Female; Gast | 1995 |
Controlled trial of high- versus low-dose aspirin treatment after percutaneous transluminal angioplasty in patients with peripheral vascular disease.
Topics: Aged; Angioplasty, Balloon; Aspirin; Double-Blind Method; Female; Gastrointestinal Diseases; Humans; | 1994 |
[Circadian aspects of acetylsalicylic acid induced injury and protective effect of ranitidine on the the upper gastrointestinal tract].
Topics: Adult; Aspirin; Circadian Rhythm; Double-Blind Method; Gastric Mucosa; Gastrointestinal Diseases; Hu | 1994 |
Comparison of piroxicam and acetylsalicylic acid for pain in head and neck cancers: a double-blind study.
Topics: Adult; Aged; Aspirin; Clinical Protocols; Double-Blind Method; Female; Gastrointestinal Diseases; He | 1994 |
European stroke prevention study 2: dipyridamole and acetylsalicylic acid in the secondary prevention of stroke.
Topics: Aged; Aspirin; Cerebrovascular Disorders; Dipyridamole; Disease-Free Survival; Double-Blind Method; | 1997 |
Comparative safety and tolerability of clopidogrel and aspirin: results from CAPRIE. CAPRIE Steering Committee and Investigators. Clopidogrel versus aspirin in patients at risk of ischaemic events.
Topics: Arteriosclerosis; Aspirin; Cerebrovascular Disorders; Clopidogrel; Double-Blind Method; Gastrointest | 1999 |
Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study.
Topics: Aged; Analysis of Variance; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Aspirin; | 2000 |
The sugar absorption test in the evaluation of the gastrointestinal intolerance to bisphosphonates: studies with oral pamidronate.
Topics: Absorption; Adolescent; Adult; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Ar | 2001 |
Prostaglandin-synthesis inhibitors in prophylaxis of food intolerance.
Topics: Acute Disease; Adult; Animals; Aspirin; Bivalvia; Chickens; Clinical Trials as Topic; Dairy Products | 1978 |
Ibuprofen in osteoarthritis.
Topics: Activities of Daily Living; Aspirin; Chemical Phenomena; Chemistry; Clinical Trials as Topic; Dextro | 1977 |
Endoscopic study of gastro-intestinal injury with non-steroidal anti-inflammatory drugs.
Topics: Adult; Aspirin; Clinical Trials as Topic; Double-Blind Method; Flurbiprofen; Gastrointestinal Diseas | 1977 |
Naproxen vs. aspirin in osteoarthritis of the hip and knee.
Topics: Adult; Aged; Aspirin; Central Nervous System Diseases; Clinical Trials as Topic; Double-Blind Method | 1978 |
Pirprofen and aspirin in the treatment of rheumatoid arthritis.
Topics: Adult; Aged; Anti-Inflammatory Agents; Arthritis, Rheumatoid; Aspirin; Clinical Trials as Topic; Dou | 1979 |
Clinical comparison of fenbufen and aspirin in osteoarthritis.
Topics: Administration, Oral; Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Biphenyl Compounds; C | 1979 |
A double-blind cross-over evaluation of ketoprofen and aspirin in rheumatoid arthritis.
Topics: Adult; Aged; Analgesics; Arthritis, Rheumatoid; Aspirin; Benzophenones; Clinical Trials as Topic; Dr | 1976 |
Two year Cottbus reinfarction study with 30 mg aspirin per day.
Topics: Aged; Aspirin; Dinoprost; Follow-Up Studies; Gastrointestinal Diseases; Germany; Hospitals, District | 1991 |
Comparison of long-term safety of ketorolac tromethamine and aspirin in the treatment of chronic pain.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Chronic Disease; D | 1990 |
United Kingdom transient ischaemic attack (UK-TIA) aspirin trial: interim results. UK-TIA Study Group.
Topics: Aged; Aspirin; Cardiovascular Diseases; Cerebrovascular Disorders; Clinical Trials as Topic; Dose-Re | 1988 |
Two double blind trials of diclofenac sodium with aspirin and with naproxen in the treatment of patients with rheumatoid arthritis.
Topics: Adult; Aged; Arthritis, Rheumatoid; Aspirin; Clinical Trials as Topic; Diclofenac; Double-Blind Meth | 1988 |
International experiences with diclofenac in osteoarthritis.
Topics: Aspirin; Clinical Trials as Topic; Diclofenac; Diflunisal; Double-Blind Method; Gastrointestinal Dis | 1986 |
Worldwide safety experience with diclofenac.
Topics: Adult; Aged; Aspirin; Chemical and Drug Induced Liver Injury; Child; Clinical Trials as Topic; Diclo | 1986 |
Ranitidine protects against gastroduodenal mucosal damage associated with chronic aspirin therapy.
Topics: Adolescent; Adult; Aspirin; Duodenum; Gastric Mucosa; Gastrointestinal Diseases; Humans; Intestinal | 1987 |
Evaluation of the safety of isoxicam.
Topics: Aged; Arthritis, Rheumatoid; Aspirin; Clinical Trials as Topic; Double-Blind Method; Drug Evaluation | 1985 |
Minimization of gastric damage with enteric-coated aspirin granules compared to buffered aspirin.
Topics: Adolescent; Adult; Aspirin; Buffers; Female; Gastric Mucosa; Gastrointestinal Diseases; Humans; Inte | 1985 |
Evaluation of indomethacin by a controlled, cross-over technique in 30 patients with ankylosing spondylitis.
Topics: Alkaline Phosphatase; Anemia, Hypochromic; Aspartate Aminotransferases; Aspirin; Central Nervous Sys | 1967 |
Double-blind study of the analgesic effect of ethoheptazine-aspirin.
Topics: Adolescent; Adult; Aged; Analysis of Variance; Aspirin; Azepines; Clinical Trials as Topic; Depressi | 1974 |
Treatment of rheumatoid arthritis with fenoprofen: comparison with aspirin.
Topics: Acetaminophen; Arthritis, Rheumatoid; Aspirin; Body Temperature; Clinical Trials as Topic; Deafness; | 1974 |
Effect of acetylsalicylic acid and dipyridamole on platelet survival and aggregation in patients with atherosclerosis obliterans.
Topics: Aged; Arteriosclerosis Obliterans; Aspirin; Blood Cell Count; Blood Platelets; Cell Survival; Clinic | 1974 |
A profile of the physiological disposition and gastro-intestinal effects of fenoprofen in man.
Topics: Administration, Oral; Adult; Age Factors; Animals; Anti-Inflammatory Agents; Aspirin; Biotransformat | 1974 |
Measurement of side effects of drugs.
Topics: Analgesics; Anti-Inflammatory Agents; Aspirin; Deafness; Drug-Related Side Effects and Adverse React | 1974 |
Ibuprofen, aspirin and placebo in the treatment of rheumatoid arthritis--a double-blind clinical trial.
Topics: Adult; Aged; Analgesics; Anti-Inflammatory Agents; Arthritis, Rheumatoid; Aspirin; Clinical Trials a | 1969 |
137 other studies available for aspirin and Cholera Infantum
| Article | Year |
|---|---|
Synthesis and biological evaluation of amide derivatives of (5,6-dimethoxy-2,3-dihydro-1H-inden-1-yl)acetic acid as anti-inflammatory agents with reduced gastrointestinal ulcerogenecity.
Topics: Acetates; Amides; Analgesics, Non-Narcotic; Animals; Anti-Inflammatory Agents, Non-Steroidal; Arthri | 2008 |
Development of the PC-NSAID technology: From contact angle to Vazalore®.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Gastrointestinal Diseases; Humans; Phosphatidylcho | 2023 |
The contribution of clinical and pathological predisposing factors to severe gastro-duodenal lesions in patients with long-term low-dose aspirin and proton pump inhibitor therapy.
Topics: Aged; Anemia; Aspirin; Atrophy; Causality; Endoscopy, Gastrointestinal; Female; Gastrointestinal Dis | 2017 |
Use of multicriteria decision analysis for assessing the benefit and risk of over-the-counter analgesics.
Topics: Analgesics; Aspirin; Decision Support Techniques; Gastrointestinal Diseases; Humans; Ibuprofen; Napr | 2017 |
Upper Gastrointestinal Complications and Cardiovascular/Gastrointestinal Risk Calculator in Patients with Myocardial Infarction Treated with Aspirin.
Topics: Aged; Aged, 80 and over; Aspirin; Female; Gastrointestinal Diseases; Humans; Logistic Models; Male; | 2017 |
[Safety and efficacy of long-term treatment with different ASA forms in patients with stable IHD and a high risk for development of gastropathy by data from a cross-sectionals study].
Topics: Aged; Aspirin; Cross-Sectional Studies; Female; Gastrointestinal Diseases; Humans; Long-Term Care; M | 2017 |
Network pharmacology-based identification of protective mechanism of Panax Notoginseng Saponins on aspirin induced gastrointestinal injury.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Databases, Factual; Gastrointestinal Dise | 2018 |
[Predictors for development of major cardiovascular events in elderly patients with severe and extremely severe chronic obstructive pulmonary disease in combination with early stages of chronic kidney disease].
Topics: Aged; Aspirin; Gastrointestinal Diseases; Humans; Prospective Studies; Pulmonary Disease, Chronic Ob | 2019 |
Ask the doctor. I need surgery for a gastrointestinal problem, and my question is how to handle my antiplatelet therapy, which I have been taking for two years since I had angioplasty. I take aspirin and clopidogrel, which were started after I had a hea
Topics: Aspirin; Clopidogrel; Contraindications; Digestive System Surgical Procedures; Dose-Response Relatio | 2012 |
Risk factor profiles, drug usage, and prevalence of aspirin-associated gastroduodenal injuries among high-risk cardiovascular Japanese patients: the results from the MAGIC study.
Topics: Aged; Aspirin; Dose-Response Relationship, Drug; Female; Gastric Mucosa; Gastrointestinal Diseases; | 2014 |
Non-steroidal anti-inflammatory drugs (NSAIDs).
Topics: Administration, Topical; Aged; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; As | 2013 |
Effect of baseline gastrointestinal risk and use of proton pump inhibitors on frequency of discontinuation of aspirin for secondary cardiovascular prevention in United kingdom primary care.
Topics: Administration, Oral; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Dose-Response Relat | 2013 |
Difference between the frequencies of antisecretory drug prescriptions in users of buffered vs. enteric-coated low-dose aspirin therapies.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Drug Prescriptions; Female; Gastrointestinal Diseases; Hist | 2013 |
[Evaluation of drug information service available for physicians regarding low-dose aspirin-induced gastrointestinal lesions].
Topics: Administration, Oral; Aspirin; Drug Information Services; Drug Synergism; Gastrointestinal Diseases; | 2014 |
Proton pump inhibitor treatment decreases the incidence of upper gastrointestinal disorders in elderly Japanese patients treated with NSAIDs.
Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Aspirin; Endosc | 2014 |
[Diclofenac: update on tolerableness and spinal anti-inflammatory action].
Topics: Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Blood-Brain Barrier; Car | 2014 |
Time-trends in the prescribing of gastroprotective agents to primary care patients initiating low-dose aspirin or non-steroidal anti-inflammatory drugs: a population-based cohort study.
Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cohort Studies; Databases | 2015 |
Concurrent Use of Low-Dose Aspirin and Omega-3 Fatty Acids and Risk of Upper Gastrointestinal Complications: A Cohort Study with Nested Case-Control Analysis.
Topics: Aged; Aspirin; Cardiovascular Diseases; Dose-Response Relationship, Drug; Drug Synergism; Drug Thera | 2016 |
Epidemiology of Upper Gastrointestinal Damage Associated with Low-Dose Aspirin.
Topics: Age Factors; Aged; Aspirin; Dose-Response Relationship, Drug; Gastrointestinal Diseases; Gastrointes | 2015 |
Primary Percutaneous Coronary Intervention in Patients With ST-Segment-Elevation Myocardial Infarction and Concurrent Active Gastrointestinal Bleeding.
Topics: Aged; Aspirin; Blood Vessel Prosthesis Implantation; Cardiopulmonary Resuscitation; Dopamine; Drug-E | 2015 |
[Long-term follow up after gastro-endoscopy screening for age ≥45 years male health care population with long-term aspirin used in gastrointestinal mucosal injury].
Topics: Aspirin; Follow-Up Studies; Gastric Mucosa; Gastrointestinal Diseases; Gastroscopy; Humans; Intestin | 2015 |
Risk of gastrointestinal complications associated to NSAIDs, low-dose aspirin and their combinations: Results of a pharmacovigilance reporting system.
Topics: Adult; Adverse Drug Reaction Reporting Systems; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspir | 2016 |
Adherence with regulatory resolutions on prevention of NSAIDS-related gastrointestinal injury in Italy.
Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Drug Utilization; Female; | 2016 |
Aspirin for cancer is no mere antiplatelet prototype. There is potential in its ancient roots.
Topics: Animals; Aspirin; Blood Platelets; Colorectal Neoplasms; Cyclooxygenase Inhibitors; Gastrointestinal | 2016 |
The budget impact of using enteric-coated aspirin 325 mg + immediate-release omeprazole 40 mg to prevent recurrent cardiovascular events.
Topics: Adult; Aged; Aspirin; Budgets; Cardiovascular Diseases; Clopidogrel; Drug Combinations; Female; Gast | 2017 |
Investigation of gastric and duodenal mucosal defects caused by low-dose aspirin in patients with ischemic heart disease.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Buffers; Drug Administration Schedule; Duode | 2009 |
[Risk and prevention of gastrointestinal complications due to low-dose aspirin and other antiplatelet agents].
Topics: Aspirin; Gastrointestinal Diseases; Humans; Platelet Aggregation Inhibitors; Risk Factors | 2008 |
The management of NSAIDs therapy: how to minimize upper gastrointestinal tract damage.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Gastrointestinal Diseases; Humans | 2008 |
Canadian consensus guidelines on long-term nonsteroidal anti-inflammatory drug therapy and the need for gastroprotection: benefits versus risks.
Topics: Aged; Aged, 80 and over; Algorithms; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Canada; Cardi | 2009 |
The prevalence of intolerance for low-dose acetylsalicylacid in the secondary prevention of atherothrombosis.
Topics: Administration, Oral; Aged; Angioedema; Aspirin; Dose-Response Relationship, Drug; Embolism, Cholest | 2009 |
[Update on gastrointestinal disorders associated with non-steroidal anti-inflammatory drugs].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Gastrointestinal Diseases; Humans; Platelet Aggreg | 2008 |
The continuing unacceptable marketing of Alka-Seltzer containing aspirin for stomach-related disorders.
Topics: Advertising; Aspirin; Citrates; Dose-Response Relationship, Drug; Drug Combinations; Gastrointestina | 2009 |
Colorectal cancer chemoprevention: ready for practice?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Aspirin; Colorectal Neoplasms; Cyclo | 2009 |
The impact of upper gastrointestinal symptoms on nonadherence to, and discontinuation of, low-dose acetylsalicylic acid in patients with cardiovascular risk.
Topics: Adult; Aged; Aspirin; Cardiovascular Diseases; Female; Gastrointestinal Diseases; Humans; Male; Medi | 2010 |
Undisclosed use of nonsteroidal anti-inflammatory drugs may underlie small-bowel injury observed by capsule endoscopy.
Topics: Anti-Inflammatory Agents; Aspirin; Capsule Endoscopy; Female; Gas Chromatography-Mass Spectrometry; | 2010 |
Renin-angiotensin system associated with risk of upper GI mucosal injury induced by low dose aspirin: renin angiotensin system genes' polymorphism.
Topics: Aged; Aged, 80 and over; Anti-Ulcer Agents; Aspirin; Case-Control Studies; Dose-Response Relationshi | 2011 |
Prevalence and clinical impact of Upper Gastrointestinal Symptoms in subjects treated with low dose aspirin: the UGLA survey.
Topics: Aged; Aged, 80 and over; Aspirin; Female; Gastrointestinal Diseases; Health Surveys; Humans; Male; M | 2012 |
Feverfew. Bachelor's buttons, Featherfew (Tanacetum parthenium L. aka Chrysanthemum parthenium L. aka Pyrethrum parthenium L.).
Topics: Arthritis, Rheumatoid; Aspirin; Drug Interactions; Gastrointestinal Diseases; Humans; Hypersensitivi | 2010 |
The novel phospho-non-steroidal anti-inflammatory drugs, OXT-328, MDC-22 and MDC-917, inhibit adjuvant-induced arthritis in rats.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Experimental; Aspirin; Cell Line; Cytok | 2011 |
[Security of proton pump inhibitors].
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Child; Chronic Disease; Drug Interactions; | 2011 |
[Investigation into the effect of gastric secretion inhibitor for the prevention of upper gastrointestinal lesions associated with low-dose aspirin].
Topics: Aspirin; Gastrointestinal Diseases; Histamine H2 Antagonists; Humans; Incidence; Proton Pump Inhibit | 2011 |
Impact of gastrointestinal problems on adherence to low-dose acetylsalicylic Acid: a quantitative study in patients with cardiovascular risk.
Topics: Adult; Aged; Aspirin; Cardiovascular Diseases; Female; Gastrointestinal Diseases; Humans; Internet; | 2011 |
Prospective cohort study of gastrointestinal complications and vascular diseases in patients taking aspirin: rationale and design of the MAGIC Study.
Topics: Aspirin; Cohort Studies; Epidemiologic Research Design; Gastrointestinal Diseases; Humans; Japan; Pl | 2011 |
The MAGIC Study and the gastrointestinal effects of low-dose aspirin : editorial to: "Prospective cohort study of gastrointestinal complications and vascular diseases in patients taking aspirin: rationale and design of the MAGIC Study" by H. Origasa et al
Topics: Aspirin; Epidemiologic Research Design; Gastrointestinal Diseases; Humans; Platelet Aggregation Inhi | 2011 |
Gastroprotection in NSAID and low-dose aspirin users: a cross-sectional study in primary care.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cross-Sectional Studies; Female; Gastrointes | 2012 |
[Advances in gastrointestinal disorders associated with non-steroidal antiinflammatory agents and aspirin].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Gastrointestinal Diseases; Humans | 2011 |
Daily low-dose aspirin: beware of GI bleeding.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Dose-Response Relationshi | 2012 |
Gastrointestinal-sparing effects of novel NSAIDs in rats with compromised mucosal defence.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Aspirin; Celecoxib; Drug Therapy, Combi | 2012 |
Interaction of Helicobacter pylori infection and low-dose aspirin in the upper gastrointestinal tract: implications for clinical practice.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Gastric Acid; Gastrointestinal Diseases; Gastroint | 2012 |
Theoretical investigation of aspirin dosage regimen to exhibit optimal antiplatelet effects and decrease risk of upper gastrointestinal lesions.
Topics: Arachidonic Acids; Aspirin; Blood Platelets; Cyclooxygenase 1; Cyclooxygenase Inhibitors; Dinoprosto | 2012 |
Clinical impact of drug-drug interaction between aspirin and prednisolone at a cancer center.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cancer Care Facilities; Drug Interactions; Female; Gastroin | 2012 |
The assessment of risk for gastrointestinal injury with anticoagulant and antiplatelet drugs: the possible beneficial effect of eicosapentaenoic Acid for the risk of gastrointestinal injury.
Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Clopidogrel; Eicosapentaenoic Acid; Female; Gastro | 2013 |
Low-dose aspirin: protection from the panacea.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; | 2002 |
An aspirin a day keeps the cardiologist away (but what about the gastroenterologist?).
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Aspirin; Dose-Response Relationship, Dru | 2003 |
Current practice in the use of antiplatelet agents in the peri-operative period by UK vascular surgeons.
Topics: Aortic Aneurysm, Abdominal; Aspirin; Consensus; Contraindications; Gastrointestinal Diseases; Humans | 2003 |
NSAID and aspirin use by the elderly in general practice: effect on gastrointestinal symptoms and therapies.
Topics: Activities of Daily Living; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Drug Utilization | 2003 |
Low frequency of upper gastrointestinal complications in a cohort of high-risk patients taking low-dose aspirin or NSAIDS and omeprazole.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Aspirin; | 2003 |
The acute oral toxicity of acetylsalicylic acid.
Topics: Aspirin; Gastrointestinal Diseases | 1959 |
The acute oral toxicity of a mixture of acetylsalicylic acid, phenacetin, and caffeine.
Topics: Aspirin; Caffeine; Gastrointestinal Diseases; Humans; Phenacetin | 1959 |
The acute oral toxicity in guinea pigs of acetylsalicylic acid, phenacetin, and caffeine, alone and combined.
Topics: Aspirin; Caffeine; Gastrointestinal Diseases; Guinea Pigs; Humans; Phenacetin | 1960 |
Rates of serious gastrointestinal events from low dose use of acetylsalicylic acid, acetaminophen, and ibuprofen in patients with osteoarthritis and rheumatoid arthritis.
Topics: Acetaminophen; Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Aspirin; Dose-R | 2003 |
Summaries for patients. Gastrointestinal side effects of rofecoxib and naproxen.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Cyclooxygenase Inhibitors | 2003 |
[Gastroduodenal injury in patients with low-dose enteric coated aspirin treatment].
Topics: Aged; Aspirin; Cardiovascular Diseases; Esophagitis; Female; Gastritis; Gastrointestinal Diseases; H | 2003 |
Cardiovascular prophylaxis with aspirin: costs of supply and management of upper gastrointestinal and renal toxicity.
Topics: Acute Kidney Injury; Aged; Aspirin; Cohort Studies; Cost of Illness; Cost-Benefit Analysis; Drug Cos | 2004 |
[Report of two cases with persimmon caused huge gastrolithiasis treated with aspirin].
Topics: Adolescent; Aspirin; Child, Preschool; Diospyros; Female; Fruit; Gastrointestinal Diseases; Humans; | 2004 |
Serious gastrointestinal events from low dose analgesic use.
Topics: Acetaminophen; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Aspirin; Dose-Respons | 2004 |
Drug-induced upper gastrointestinal disorders requiring hospitalization: a five-year study in a South Indian hospital.
Topics: Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Drug-Related Side Effects a | 2004 |
Risks of clinically significant upper gastrointestinal events with etodolac and naproxen: a historical cohort analysis.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cohort Studies; Cy | 2004 |
Rofecoxib, Merck, and the FDA.
Topics: Aspirin; Cardiovascular Diseases; Celecoxib; Cyclooxygenase Inhibitors; Drug Approval; Drug Interact | 2004 |
Optimizing cardiovascular and chemopreventive benefits of aspirin: what role for the proton-pump inhibitors?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Colorectal Neoplasms; Eso | 2005 |
Counting the true cost of antiplatelet therapy for stroke prevention.
Topics: Aged; Aspirin; Aspirin, Dipyridamole Drug Combination; Clopidogrel; Cost-Benefit Analysis; Dipyridam | 2005 |
A nationwide study of mortality associated with hospital admission due to severe gastrointestinal events and those associated with nonsteroidal antiinflammatory drug use.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Female; Gastrointestinal Diseases; Gastroint | 2005 |
NSAID-associated deaths: the rise and fall of NSAID-associated GI mortality.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Gastrointestinal Diseases; Humans; Spain | 2005 |
Adverse effects of etoricoxib: other considerations.
Topics: Aspirin; Cardiovascular Diseases; Cyclooxygenase Inhibitors; Dose-Response Relationship, Drug; Drug | 2005 |
Polymorphisms in genes encoding acetylsalicylic acid metabolizing enzymes are unrelated to upper gastrointestinal health in cardiovascular patients on acetylsalicylic acid.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aryl Hydrocarbon Hydroxylases; Aspirin; Cardiovascula | 2005 |
The prevalence of risk factors for gastrointestinal complications and use of gastroprotection among persons hospitalized for cardiovascular disease.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Enzyme Inhibitors; | 2006 |
What price pain relief?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Blood Pressure; Cardiovascular Diseases; Cyclooxyg | 2006 |
Consensus development conference on the use of nonsteroidal anti-inflammatory agents, including cyclooxygenase-2 enzyme inhibitors and aspirin.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Cyclooxygenase 2 Inhibito | 2006 |
Gastrointestinal complications of over-the-counter nonsteroidal antiinflammatory drugs.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Child; | 2006 |
Cardioprotective aspirin users and their excess risk of upper gastrointestinal complications.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiotonic Agents | 2006 |
Risk of low-dose aspirin: emphasis on outliers undermines the credibility of the conclusions.
Topics: Adrenal Cortex Hormones; Aging; Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Aspirin; Ca | 2007 |
Risk of upper gastrointestinal complications among users of traditional NSAIDs and COXIBs in the general population.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Anticoagulants; Aspirin; Case-Control St | 2007 |
Summaries for patients. Aspirin or nonsteroidal anti-inflammatory drugs for the prevention of colorectal cancer: U.S. Preventive Services Task Force recommendations.
Topics: Adenoma; Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Colonic Polyps; Colorectal Neoplas | 2007 |
Routine aspirin or nonsteroidal anti-inflammatory drugs for the primary prevention of colorectal cancer: U.S. Preventive Services Task Force recommendation statement.
Topics: Adenoma; Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Colonic Polyps; Colorectal Neoplas | 2007 |
Gastrointestinal symptoms in patients with end-stage renal disease undergoing treatment by hemodialysis or peritoneal dialysis.
Topics: Abdominal Pain; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cross-Sectional Studies; Dyspepsia | 2008 |
Controlled trial of clinical utility of serum salicylate monitoring in rheumatoid arthritis.
Topics: Arthritis, Rheumatoid; Aspirin; Deafness; Double-Blind Method; Drug Administration Schedule; Evaluat | 1984 |
Effect of a single dose of regular and soluble aspirin on the gastric and duodenal mucosa.
Topics: Adolescent; Adult; Aspirin; Duodenum; Gastric Mucosa; Gastrointestinal Diseases; Humans; Intestinal | 1984 |
Primary drug therapy: aspirin vs. the nonsteroidal anti-inflammatory drugs.
Topics: Anti-Inflammatory Agents; Arthritis; Aspirin; Central Nervous System Diseases; Chemical and Drug Ind | 1983 |
Preclinical studies on indoprofen, a new non-steroidal analgesic-antiinflammatory agent.
Topics: Animals; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Carrageenan; Do | 1981 |
Effects of 16,16-dimethyl-PGE2-methyl ester on aspirin- and indomethacin-induced gastric and intestinal lesions in mini pigs.
Topics: 16,16-Dimethylprostaglandin E2; Animals; Aspirin; Female; Gastrointestinal Diseases; Indomethacin; I | 1983 |
Effect of aspirin on the human stomach in normals: endoscopic comparison of damage produced one hour, 24 hours, and 2 weeks after administration.
Topics: Adult; Aspirin; Double-Blind Method; Endoscopy; Female; Gastric Mucosa; Gastrointestinal Diseases; H | 1981 |
Gastrointestinal consequences of treatment with drugs in elderly patients.
Topics: Aged; Aging; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Digestive System Physiological Phenom | 1982 |
[Gastroduodenal lesions in rheumatoid arthritis, mesenchymopathies and other rheumatisms. Endoscopic study].
Topics: Anti-Inflammatory Agents; Arthritis, Rheumatoid; Aspirin; Female; Gastrointestinal Diseases; Gastros | 1982 |
Local buccal mucosal effects of aspirin, indomethacin and isoxepac: their relationship to gastrointestinal damage.
Topics: Acetates; Anti-Inflammatory Agents; Aspirin; Cheek; Dibenzoxepins; Gastrointestinal Diseases; Humans | 1981 |
Studies of myocardial infarction.
Topics: Aspirin; Dipyridamole; Drug Combinations; Gastrointestinal Diseases; Humans; Myocardial Infarction; | 1980 |
[Survey of pathologies caused by sulfites in allergology].
Topics: Adolescent; Adult; Aspirin; Child; Cross Reactions; Drug Eruptions; Drug Hypersensitivity; Female; F | 1994 |
Aspirin and coronary artery diseases.
Topics: Aspirin; Coronary Disease; Gastrointestinal Diseases; Humans; Platelet Aggregation | 1993 |
Variability in the risk of major gastrointestinal complications from nonaspirin nonsteroidal anti-inflammatory drugs.
Topics: Administration, Oral; Administration, Rectal; Adolescent; Adult; Age Factors; Aged; Aged, 80 and ove | 1993 |
Effects of aspirin and Helicobacter pylori on the gastroduodenal mucosal permeability to sucrose.
Topics: Adult; Aspirin; Biomarkers; Chromatography, High Pressure Liquid; Female; Gastric Mucosa; Gastrointe | 1996 |
Clinical consequences of nonnarcotic analgesic use.
Topics: Acetaminophen; Analgesics, Non-Narcotic; Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; | 1997 |
Discrimination of site-specific alterations in gastrointestinal permeability in the rat.
Topics: Animals; Aspirin; Biological Transport; Cyclooxygenase Inhibitors; Digestive System; Disease Models, | 1998 |
Discrimination of site-specific alterations in gastrointestinal permeability in the rat.
Topics: Animals; Aspirin; Biological Transport; Cyclooxygenase Inhibitors; Digestive System; Disease Models, | 1998 |
Discrimination of site-specific alterations in gastrointestinal permeability in the rat.
Topics: Animals; Aspirin; Biological Transport; Cyclooxygenase Inhibitors; Digestive System; Disease Models, | 1998 |
Discrimination of site-specific alterations in gastrointestinal permeability in the rat.
Topics: Animals; Aspirin; Biological Transport; Cyclooxygenase Inhibitors; Digestive System; Disease Models, | 1998 |
Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Coronary Disease; Gastrointestinal Diseases; Human | 1999 |
Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs.
Topics: Analgesics, Non-Narcotic; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Biological Availability; | 1999 |
Comparison of the effects of acetylsalicylic acid, ticlopidine and cilostazol on primary hemostasis using a quantitative bleeding time test apparatus.
Topics: Adult; Aspirin; Bleeding Time; Cilostazol; Fibrinolytic Agents; Gastrointestinal Diseases; Headache; | 1999 |
The real cost of aspirin.
Topics: Aged; Aspirin; Cost-Benefit Analysis; Female; Gastrointestinal Agents; Gastrointestinal Diseases; He | 2000 |
Aspirin, like all other drugs, is a poison.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Contraindications; Gastrointestinal Diseases; Long | 2000 |
[Clinical approach for the patient requiring non-steroid anti-inflammatory agents: role of COX-2 inhibitors].
Topics: Algorithms; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cyclooxygenase 2; Gastrointestinal Dis | 2001 |
The coxibs, selective inhibitors of cyclooxygenase-2.
Topics: Acute Kidney Injury; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Cycl | 2001 |
Editorial: Aspirin, prostaglandins, and the gut.
Topics: Aspirin; Gastrointestinal Diseases; Humans; Prostaglandin Antagonists; Prostaglandins E | 1975 |
Influence of non-steroid anti=inflammatory drugs (NSAIDd) on hepatic tyrosine aminotransferase (TA) activity in rats in vitro and in vivo.
Topics: Administration, Oral; Adrenalectomy; Animals; Anti-Inflammatory Agents; Aspirin; Dose-Response Relat | 1975 |
Effects of cancer treatment on nutrition and gastrointestinal function.
Topics: Antineoplastic Agents; Aspirin; Digestive System; Dose-Response Relationship, Radiation; Gastrointes | 1979 |
Inhibition by aspirin of gastrointestinal toxicity induced by indomethacin in polyarthritic rats.
Topics: Animals; Arthritis; Arthritis, Experimental; Aspirin; Disease Models, Animal; Dose-Response Relation | 1979 |
Comparisons of tolerability findings in international clinical trials.
Topics: Arthritis, Rheumatoid; Aspirin; Cardiovascular System; Clinical Trials as Topic; Diclofenac; Drug To | 1979 |
Unusual abdominal complications of a suicidal overdose of analgesic and psychotropic drugs in an elderly patient.
Topics: Aged; Amitriptyline; Aspirin; Blind Loop Syndrome; Diazepam; Enteritis; Female; Gastrointestinal Dis | 1978 |
[Gastrointestinal diseases caused by drugs, especially by anti-inflammatory agents].
Topics: Animals; Anti-Inflammatory Agents; Aspirin; Betamethasone; Dogs; Gastrointestinal Diseases; Indometh | 1978 |
A profile of the gastrointestinal toxicity of aspirin, indomethacin, oxaprozin, phenylbutazone, and fentiazac in arthritic and Lewis normal rats.
Topics: Acetates; Animals; Anti-Inflammatory Agents; Arthritis; Arthritis, Experimental; Aspirin; Body Weigh | 1977 |
Mortality among arthritics.
Topics: Aged; Arthritis, Rheumatoid; Aspirin; Cardiovascular Diseases; Central Nervous System Diseases; Coro | 1976 |
Diseases of the alimentary system. Gastrointestinal reactions to drugs.
Topics: Adrenal Cortex Hormones; Anti-Bacterial Agents; Aspirin; Constipation; Dyspepsia; Gastrointestinal D | 1976 |
Interaction studies of tilomisole, aspirin, and naproxen in acute and chronic inflammation with assessment of gastrointestinal irritancy in the rat.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Experimental; Aspirin; Benzimidazoles; | 1992 |
Nonsteroidal anti-inflammatory drug toxicosis in dogs and cats: 240 cases (1989-1990)
Topics: Accidents; Acetaminophen; Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cat Diseases; C | 1992 |
Drug-related admissions to a department of medical gastroenterology. The role of self-medicated and prescribed drugs.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Denmark; Female; G | 1991 |
[Adverse effects of non-steroidal antirheumatic drugs with special reference to the gastrointestinal tract].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Aspirin; Drug Hypersensitivity; Gast | 1987 |
Salicylate toxicity in elderly patients with rheumatoid arthritis.
Topics: Adult; Age Factors; Aged; Arthritis, Rheumatoid; Aspirin; Central Nervous System Diseases; Dose-Resp | 1987 |
Aspirin dosing using 15 grain enteric coated tablets.
Topics: Adult; Aged; Arthritis, Rheumatoid; Aspirin; Female; Gastrointestinal Diseases; Humans; Male; Middle | 1985 |
Adverse reactions to non-steroidal antirheumatic drugs.
Topics: Analgesics; Animals; Anti-Inflammatory Agents; Aspirin; Benzophenones; Chemical and Drug Induced Liv | 1974 |
[Undesired collateral effects of salicylates].
Topics: Anemia; Arthritis, Rheumatoid; Aspirin; Blood Coagulation Disorders; Dysautonomia, Familial; Gastroi | 1972 |
[Gastro-duodenal tolerance of some drugs with analgesic effect. Clinico-endoscopic considerations].
Topics: Analgesics; Anti-Inflammatory Agents; Antimalarials; Aspirin; Digestive System; Duodenal Ulcer; Esop | 1974 |
[Adverse effects of acetylosalicylic acid].
Topics: Aspirin; Gastrointestinal Diseases; Humans; Hypoglycemia; Kidney Diseases | 1973 |
Recognizing and avoiding adverse gastrointestinal effects of drugs.
Topics: Aged; Antacids; Aspirin; Colon; Digestive System; Drug Antagonism; Drug Interactions; Drug-Related S | 1974 |
Wy 23205, a new non-steroidal anti-inflammatory agent.
Topics: Animals; Anti-Inflammatory Agents; Arthritis; Aspirin; Bradykinin; Gastrointestinal Diseases; Guinea | 1971 |
[Aspirin in the treatment of myocardial infarct].
Topics: Aspirin; Bicarbonates; Blood Coagulation; Blood Sedimentation; Gastrointestinal Diseases; Hematuria; | 1971 |
[Electron microscopy studies on the gastrointestinal intolerance of various drugs].
Topics: Aspirin; Chloramphenicol; Drug Hypersensitivity; Epithelial Cells; Gastrointestinal Diseases; Humans | 1971 |
[Complications in the gastrointestinal tract during antirheumatic therapy].
Topics: Adult; Aspirin; Female; Gastrointestinal Diseases; Gastrointestinal Hemorrhage; Humans; Male; Middle | 1968 |
[Digestive disorders from drug origin. I. Gastrointestinal lesions].
Topics: Adrenal Cortex Hormones; Anti-Bacterial Agents; Anti-Inflammatory Agents; Anticoagulants; Aspirin; C | 1971 |
[Current analgesic anti-inflammatory drugs].
Topics: Analgesics; Aniline Compounds; Anti-Inflammatory Agents; Aspirin; Chemical and Drug Induced Liver In | 1970 |
Seizures and fever.
Topics: Acetaminophen; Acidosis, Respiratory; Age Factors; Alkalosis, Respiratory; Aspirin; Brain Diseases; | 1971 |
Aspirin-induced gastrointestinal lesions in dogs.
Topics: Animals; Aspirin; Dog Diseases; Dogs; Duodenal Ulcer; Female; Gastrointestinal Diseases; Male; Stoma | 1968 |